The Acquirers Podcast

David Ferrero on Times Square Capital's quality growth biotech strategy and AI limitations

1h 5m Listen to the original Episode page
BiotechSmall-capValue InvestingAI in HealthcarePortfolio ConstructionRisk ManagementInterest RatesClinical Trials

Summary

David Ferrero of Times Square Capital Management discusses his firm's quality growth approach, focusing on small to mid-cap US and international equities with an emphasis on commercial-stage biotech to mitigate binary risk. He explains that biotech returns are power-law driven, relying on binary events like data readouts, and details how the fund balances high-risk developmental assets with commercial businesses. Ferrero also addresses the impact of interest rates on sector bifurcation, noting that commercial companies have outperformed developmental ones in higher-rate environments. Finally, he evaluates the current state of AI in drug discovery, arguing that while AI improves early-stage efficiency, it has not yet proven effective for Phase 2 to Phase 3 success rates.

Episode sections

  1. 0:00 – 1:27

    Sponsor Reads and Intro

    The episode begins with sponsor reads for IG Private Wealth and The Score Bet sportsbook, followed by hosts Tobias Carlisle and Jake Taylor introducing guest David Ferrero.

  2. 1:27 – 4:26

    Firm Overview and Investment Philosophy

    David Ferrero describes Times Square Capital Management as a 25-year-old boutique asset manager focusing on small to mid-cap US and international equities. He defines their 'quality growth' approach as seeking companies with sustainable competitive advantages, strong management teams, and consistent growth, while avoiding momentum chasing.

  3. 4:26 – 8:20

    Background and Transition to Finance

    Ferrero explains his transition from a PhD in microbiology and immunology to Wall Street. He leveraged his scientific training to understand complex healthcare subjects and applied rigorous analytical skepticism to stock picking, starting his career in sell-side biotech research.

  4. 8:20 – 13:31

    Biotech Investment Strategy and Case Study

    Ferrero discusses investing in later-stage biotech (post-Phase 2) to mitigate binary risk, using Mirati Pharmaceuticals as a case study. He highlights Mirati's commercial franchise, strong management team, and pipeline assets for rare liver diseases like PSC and PBC, noting the company's ability to acquire and commercialize assets effectively.

  5. 13:31 – 18:03

    Market Inefficiencies in Biotech

    The hosts and guest discuss why biotech stocks are mispriced. Ferrero attributes this to investor aversion to uncertainty and ambiguity, particularly regarding clinical trial risks and rare disease market sizes, which allows investors to earn outsized returns by taking educated risks on undervalued commercial franchises and pipelines.

  6. 18:03 – 19:44

    Biotech Investment Profile and Return Drivers

    Speaker_2 characterizes the fund as traditional value but notes biotech growth is often early-stage and potentially venture-capital-like. Speaker_0 explains that returns are spiky and power-law driven, with multi-baggers occurring from binary events like data readouts or takeouts, while established businesses offer steadier, double-digit percentage upside.

  7. 19:44 – 22:05

    Portfolio Construction and Position Sizing

    The fund is a long-only small-cap growth product that balances higher-risk binary assets with commercial businesses to avoid purely binary outcomes. Position sizing varies significantly: commercial companies like Mirna Therapeutics can be top-10 positions (100-200 basis points active weight), while early-stage 'hero-zero' companies are limited to 25-50 basis points due to the risk of losing a majority of the position.

  8. 22:05 – 23:05

    Portfolio Diversification and Team Structure

    The portfolio holds between 75 and 100 positions in the small-cap landscape. To manage this breadth, the firm employs a team approach with separate groups covering healthcare, industrials, consumer, energy, and tech, rather than relying on a single manager.

  9. 23:05 – 24:42

    Interest Rates and Sector Bifurcation

    Biotech is sensitive to the cost of capital, with an inverse correlation to yields. However, recent rate hikes coincided with AI spending fears, causing money to flow into healthcare as a safe haven. This has created a bifurcation where commercial-stage companies are favored in higher-rate environments, while developmental-stage companies face pressure.

  10. 24:42 – 26:35

    Valuation Discounts and Pipeline Value

    Speaker_0 notes that while large-cap biopharma might trade at discounts to net cash with free pipelines, this is less common in small-caps. However, medical devices have traded at historic lows, and the fund believes Mirna Therapeutics offers a substantial discount on its pipeline relative to its commercial business.

  11. 26:35 – 29:27

    AI in Drug Discovery: Efficiency vs. Biology

    AI has improved efficiency in designing molecules and speeding up the path to Phase 1/2 trials, with some evidence of increased success rates from Phase 1 to Phase 2. However, AI has not yet improved success rates from Phase 2 to Phase 3, which is considered the true proof of biology and disease impact.

  12. 29:27 – 33:24

    AI Applications and Limitations in Clinical Trials

    AI is helping with patient enrollment and selection, addressing a major cause of trial halts. However, AI cannot shorten the biological duration of trials, such as the 3.5 years required for an Alzheimer's prevention trial. Isomorphic Labs, backed by Demis Hassabis and Google DeepMind, has raised over $2 billion to address these biological challenges.

  13. 33:24 – 40:35

    Investment Discipline and Risk Management

    Speaker_0 uses Ed Viesturs' mountaineering philosophy ('getting down is mandatory') to illustrate investment discipline. He warns against 'summit fever' where success leads to overconfidence and relaxed risk rules. He cites Isaac Newton's loss in the South Sea Bubble as an example of undoing previous gains by ignoring established limits during a bull market.

  14. 40:35 – 1:05:29

    Variance Drain and Risk Management

    Speaker_0 discusses the concept of variance drain, noting that while avoiding big losses preserves capital for future opportunities, it can lead to missing significant upside. He uses the analogy of mountaineer Ed Viesturs, who prioritizes getting home safely over reaching the summit, to illustrate sensible risk management in investing.

Assets discussed

AssetKindStanceContext
S&P 500indexneutralAnd if you look at the chart of the SP for 500, if you go back, it looks like a big mountain.

“Stance” is how the speakers talked about the asset, not a recommendation.

Claims worth verifying

Biotech returns are spiky and power-law driven, with multi-baggers coming from binary events like data readouts or takeouts.

Unidentified speaker (UNKNOWN) ·18:54

How to verify: Review historical stock price movements of small-cap biotech companies around FDA approval dates or M&A announcements to confirm the magnitude of price jumps relative to steady growth periods. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.

The fund is a long-only small-cap growth product that balances binary assets with commercial businesses.

Unidentified speaker (speaker_0) ·19:51

How to verify: Check the fund's prospectus or website for asset class description and portfolio holdings to confirm the mix of commercial vs. developmental stage companies. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.

Mirna Therapeutics is a top-10 position with 100-200 basis points of active weight because it is a profitable commercial business.

Unidentified speaker (speaker_3) ·21:32

How to verify: Review the fund's latest 13F filing or quarterly portfolio disclosure to verify the position size and ranking of Mirna Therapeutics. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.

Primary source

The portfolio holds between 75 and 100 positions in the small-cap landscape.

Unidentified speaker (UNKNOWN) ·22:14

How to verify: Check the fund's 13F filing for the total number of equity holdings. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.

Primary source

Biotech has an inverse correlation to yields, but recent rate hikes coincided with AI fears, driving money into healthcare.

Unidentified speaker (UNKNOWN) ·23:48

How to verify: Analyze the correlation between biotech ETF performance (e.g., XBI) and Treasury yields, and cross-reference with capital flow data from the period of recent rate hikes. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.

Isomorphic Labs has raised over $2 billion.

Unidentified speaker (UNKNOWN) ·30:17

How to verify: Search for press releases or SEC filings (Form D) from Isomorphic Labs regarding funding rounds and total capital raised. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.

Primary source

Demis Hassabis is the CEO of Isomorphic Labs and won the Nobel Prize for AlphaFold.

Unidentified speaker (UNKNOWN) ·30:00

How to verify: Check Isomorphic Labs' official website for leadership bios and Nobel Prize official records for Demis Hassabis. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.

AI has improved success rates from Phase 1 to Phase 2 but not Phase 2 to Phase 3.

Unidentified speaker (UNKNOWN) ·28:51

How to verify: Search for academic papers or industry reports (e.g., from BIO International or Nature Reviews Drug Discovery) citing AI's impact on clinical trial success rates by phase. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.

Ed Viesturs summited 14 peaks over 8,000 meters without supplemental oxygen.

Unidentified speaker (speaker_0) ·35:14

How to verify: Verify against Ed Viesturs' autobiography 'No Shortcuts to the Top' or mountaineering records. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.

Isaac Newton lost his fortune in the South Sea Bubble after buying back in at higher prices.

Unidentified speaker (speaker_0) ·39:21

How to verify: Check historical financial records or biographies of Isaac Newton regarding his investments in the South Sea Company in 1720. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.

Speaker_0 mentions a scenario of 400% gains where five times the remaining money is needed to get back to the starting point.

Unidentified speaker (speaker_0) ·40:35

How to verify: This is a rhetorical illustration of variance drain; verify by checking the speaker's explanation of risk/reward asymmetry in the transcript. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.

Ed Viesturs spent 18 years chasing the 14 highest mountains and reached his last summit in May 2005.

Unidentified speaker (UNKNOWN) ·41:20

How to verify: Verify via Ed Viesturs' book 'Strong enough to go soft' or his official website/biography. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.

Speaker_3 states that breaching a downside price target is a predictor that the initial thesis is wrong.

Unidentified speaker (speaker_3) ·44:30

How to verify: This is a stated investment philosophy; verify by reviewing the firm's (TSCMLC) published investment process or methodology documents. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.

Clinical trials can cost tens of thousands of dollars per patient per year.

Unidentified speaker (speaker_3) ·47:33

How to verify: Verify via industry reports from the Tufts Center for Drug Development or Deloitte's 'Cost of New Drug Development For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.

Theranos used traditional lab equipment to run blood tests.

Unidentified speaker (speaker_3) ·50:32

How to verify: Verify via SEC enforcement actions against Theranos, court documents, or journalistic investigations like the Wall Street Journal's reporting. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.

Primary source

Revolution Medicines' drug doubled overall survival in refractory PDAC.

Unidentified speaker (speaker_3) ·54:51

How to verify: Verify via the FDA approval package for Revolution Medicines' drug (e.g., RVX-2026 or similar, check specific drug name in transcript or press releases) and the associated clinical trial data published in peer-reviewed journals. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.

Revolution Medicines first quarter sales beat street estimates by 4x.

Unidentified speaker (speaker_3) ·55:22

How to verify: Verify via Revolution Medicines' Q1 earnings press release and SEC 8-K filings for the relevant quarter. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.

Primary source

Patent life for small molecules is 20 years from invention.

Unidentified speaker (speaker_3) ·57:28

How to verify: Verify via USPTO patent law or FDA guidance on patent term extensions. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.

Med tech companies are often profitable and have real revenues, unlike unprofitable biotechs.

Unidentified speaker (speaker_3) ·1:02:51

How to verify: Verify via financial data for public med tech companies (e.g., S&P 500 Health Care sector) comparing profitability metrics to small cap biotech indices. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.

Do your own research

  • Verify Times Square Capital Management's AUM and historical performance via SEC Form ADV Part 2A.
  • Check Mirna Therapeutics' (MRNA) latest 10-K and 10-Q filings for commercial revenue trends and pipeline status.
  • Review Revolution Medicines' (RVMD) recent earnings reports and FDA approval documents for the pancreatic cancer drug.
  • Analyze clinical trial success rates from Phase 1 to Phase 2 versus Phase 2 to Phase 3 using databases like BiopharmCatalyst or ClinicalTrials.gov.
  • Assess Isomorphic Labs' funding rounds and partnership announcements with Google DeepMind via press releases or Crunchbase.
  • Compare small-cap biotech valuations to large-cap peers using net cash and pipeline discount models from financial data providers like Bloomberg or FactSet.
  • Investigate the specific patient enrollment strategies and costs for Alzheimer's trials to validate the 3.5-year timeline claim.
  • Review Theranos' historical SEC enforcement actions and court documents to understand the institutional vs. retail investor skepticism dynamics.
Full transcriptexpand
0:00
Unidentified speaker (speaker_0): Okay. When I sell my business, I want the best tax and investment advice. I want to help my kids, and I want to give back to the community. Ooh, then it's the vacation of a lifetime.
0:12
Unidentified speaker (UNKNOWN): I
0:12
Unidentified speaker (speaker_0): wonder if my out of office has a forever setter.
0:15
Unidentified speaker (UNKNOWN): An
0:15
Unidentified speaker (speaker_1): IG private wealth advisor creates the clarity you need with plans that harmonize your business, your family, and your dreams. Get financial advice that puts you at the center. Find your advice. advisor at IGPrivatewealth.com.
0:30
Unidentified speaker (UNKNOWN): Your
0:30
Unidentified speaker (speaker_2): Uncle Dale is the undisputed king of hot takes. Buffalo, they're a lot because his barber said so. Don't listen to Dale. Go with the score bet. Breaking news, live odds, and real time stats right at your fingertips. Everything you need for game day is one tap away. Don't go with hot takes, go with the score bet. Please play responsibly, 18 years or older.
0:49
Unidentified speaker (UNKNOWN): If
0:49
Unidentified speaker (speaker_3): gambling is affecting your mentality, mental health or well being, help is available. In Alberta, call or text 211 or visit ab.211.ca. Standard message and data rates may apply.
1:02
Unidentified speaker (UNKNOWN): And we're live. This is Value After Hours. I'm Tobias
1:06
Unidentified speaker (speaker_2): Carlisle,
1:06
Unidentified speaker (UNKNOWN): joined as always by my co host Jake
1:08
Unidentified speaker (speaker_2): Taylor.
1:08
Unidentified speaker (UNKNOWN): Our
1:08
Unidentified speaker (speaker_2): special guest today
1:09
Unidentified speaker (UNKNOWN): is
1:09
Unidentified speaker (speaker_2): David Ferrero.
1:11
Unidentified speaker (UNKNOWN): He is uh the small
1:13
Unidentified speaker (speaker_2): cap
1:14
Unidentified speaker (UNKNOWN): portfolio.
1:15
Unidentified speaker (speaker_2): manager and healthcare analyst at Times
1:17
Unidentified speaker (UNKNOWN): Square Capital Management. Welcome, Dave. How are you? Good,
1:20
Unidentified speaker (speaker_2): thanks.
1:21
Unidentified speaker (UNKNOWN): Thanks for
1:21
Unidentified speaker (speaker_2): having
1:21
Unidentified speaker (UNKNOWN): me. So
1:22
Unidentified speaker (speaker_2): tell us a little bit, first of all, about
1:25
Unidentified speaker (UNKNOWN): what is
1:25
Unidentified speaker (speaker_2): Times Square Capital Management?
1:27
Unidentified speaker (UNKNOWN): Yeah, we're we're
1:28
Unidentified speaker (speaker_2): a small cap to mid cap uh boutique asset manager, long only. Uh, we've been around for more than 25 years.
1:35
Unidentified speaker (UNKNOWN): Um, the
1:35
Unidentified speaker (speaker_2): firm's a partnership model. We have um three flagships. flagship strategies that focus on small and mid cap in the US, and then another international small cap product. Those are our three biggest strategies. We're a vehicle agnostic firm, so
1:49
Unidentified speaker (UNKNOWN): we
1:49
Unidentified speaker (speaker_2): really cater our clients.
1:51
Unidentified speaker (UNKNOWN): We have
1:51
Unidentified speaker (speaker_2): both SMAs and mutual funds.
1:54
Unidentified speaker (UNKNOWN): More recently,
1:54
Unidentified speaker (speaker_2): we've seen a lot of
1:55
Unidentified speaker (UNKNOWN): great
1:55
Unidentified speaker (speaker_2): growth in our CIT offerings, and
1:57
Unidentified speaker (UNKNOWN): we
1:57
Unidentified speaker (speaker_2): launched
1:57
Unidentified speaker (UNKNOWN): our
1:58
Unidentified speaker (speaker_2): first ETF this year, which is a concentrated
2:00
Unidentified speaker (UNKNOWN): version of
2:01
Unidentified speaker (speaker_2): our mid-cap
2:02
Unidentified speaker (UNKNOWN): fund.
2:03
Unidentified speaker (speaker_2): And uh tell us a little bit about you describe yourself as quality growth and growth with a conscience. That was one of the things that I was most interested in hearing. How do you how do you define
2:12
Unidentified speaker (UNKNOWN): that? Yeah, so it's
2:13
Unidentified speaker (speaker_2): it's
2:14
Unidentified speaker (UNKNOWN): a
2:14
Unidentified speaker (speaker_2): good question. So
2:15
Unidentified speaker (UNKNOWN): um uh
2:15
Unidentified speaker (speaker_2): we say we're quality growth uh because one, we do focus on growth. Uh so we look for companies that are growing, and uh in our process really um highlights certain types type of companies. We look for companies that have a sustainable competitive advantage.
2:31
Unidentified speaker (UNKNOWN): Um, and
2:32
Unidentified speaker (speaker_2): that can come in the form of proprietary products, uh, you know, manufacturing, a distribution edge, barriers to entries, um, you know, maybe no competition in the markets that they're in, intellectual property moats,
2:43
Unidentified speaker (UNKNOWN): um,
2:43
Unidentified speaker (speaker_2): and most importantly, a strong consistent growth profile.
2:46
Unidentified speaker (UNKNOWN): Um,
2:47
Unidentified speaker (speaker_2): and another aspect of our process that lends to quality is we really look for high-quality management teams. This is like a qualitative assessment of management. It's something that
2:57
Unidentified speaker (speaker_2): we've built over time. We spent a lot of time on this one, we found that leadership can be a real key determinant of a successful investment. And, you know, honestly, that's especially important on the small
3:10
Unidentified speaker (UNKNOWN): cap side when a great
3:11
Unidentified speaker (speaker_3): idea could be ruined by a poor management team.
3:13
Unidentified speaker (UNKNOWN): So it's an
3:14
Unidentified speaker (speaker_3): important thing. for us
3:15
Unidentified speaker (UNKNOWN): to look for. Um and
3:17
Unidentified speaker (speaker_3): I guess when you think
3:18
Unidentified speaker (UNKNOWN): about growth with the
3:20
Unidentified speaker (speaker_3): contents, I
3:21
Unidentified speaker (UNKNOWN): guess
3:21
Unidentified speaker (speaker_3): the the key determinant there is
3:22
Unidentified speaker (UNKNOWN): that um
3:25
Unidentified speaker (UNKNOWN): we are uh
3:26
Unidentified speaker (speaker_3): not momentum chasers.
3:28
Unidentified speaker (UNKNOWN): So we're really, you know,
3:29
Unidentified speaker (speaker_3): fundamentally
3:29
Unidentified speaker (UNKNOWN): driven, really
3:30
Unidentified speaker (speaker_3): stick
3:30
Unidentified speaker (UNKNOWN): to our process. Um so it's really just an
3:33
Unidentified speaker (speaker_3): idea that we're looking for
3:34
Unidentified speaker (UNKNOWN): quality in all aspects of the business, both from a from a business standpoint and a management standpoint. Does conscience mean valuation sensitivity? No. You know, in in well, I shouldn't say no. I mean, we obviously do care about valuation. Uh, we're not going to buy it at any price. We set price targets, you know, both upside and downside price targets and
3:53
Unidentified speaker (UNKNOWN): base case price targets to help guide our investment and understand, you know, exit and entry. Um, but I think, you know, what you're asking may lend towards more. of a uh, you know, a GARPY type
4:04
Unidentified speaker (speaker_2): or value-based investment process.
4:06
Unidentified speaker (UNKNOWN): You
4:06
Unidentified speaker (speaker_2): know, that isn't the first point where we start. We don't start with the valuation.
4:10
Unidentified speaker (UNKNOWN): We
4:10
Unidentified speaker (speaker_2): start with the merits of the business. We really look for for great quality businesses and great management teams,
4:15
Unidentified speaker (UNKNOWN): and
4:16
Unidentified speaker (speaker_2): then come back to valuation and and decide, you
4:19
Unidentified speaker (UNKNOWN): know,
4:19
Unidentified speaker (speaker_2): what the right entry or exit point is
4:21
Unidentified speaker (UNKNOWN): from there.
4:22
Unidentified speaker (UNKNOWN): Uh
4:23
Unidentified speaker (speaker_2): Deb, Dave, you got a an interesting background. You got a PhD.
4:26
Unidentified speaker (UNKNOWN): What Well,
4:26
Unidentified speaker (speaker_2): what's what's your PhD in, and how did you transition from
4:29
Unidentified speaker (UNKNOWN): uh
4:30
Unidentified speaker (speaker_2): scientific research to finance?
4:33
Unidentified speaker (UNKNOWN): Yeah, yeah. So um I um as as we were talking about before, I'm a scientist by training. I studied biology in undergrad and then uh went to the Albanine Science College of Medicine and did a PhD in microbiology Biology and immunology. Um so I you know I was a scientist, you know, up until up until the end. the one benefit about being in the New York City area is that
4:53
Unidentified speaker (UNKNOWN): you do have proximity to Wall Street. This was in the early
4:56
Unidentified speaker (speaker_2): 2000s.
4:57
Unidentified speaker (UNKNOWN): So, you know, finishing grad school
4:59
Unidentified speaker (speaker_3): was pre uh, it was uh you know, pre-LinkedIn time. So finding a job probably wasn't as easy as it is now, or finding those openings weren't as easy as they are now. Um, but because of proximity to to Wall Street, you know, you'd imagine that um
5:13
Unidentified speaker (speaker_3): some scientists from the New York City area find their way into Wall Street careers, whether it
5:18
Unidentified speaker (UNKNOWN): be
5:18
Unidentified speaker (speaker_3): on the sell side or the buy side and higher tech areas like biotech,
5:22
Unidentified speaker (UNKNOWN): um,
5:23
Unidentified speaker (speaker_3): pharma.
5:24
Unidentified speaker (UNKNOWN): Um,
5:24
Unidentified speaker (speaker_3): and uh I'd heard of
5:26
Unidentified speaker (UNKNOWN): you know this career path. Uh as it as it turned out, a few of my classmates a year years ahead of me
5:31
Unidentified speaker (speaker_2): had find their way, had found their
5:33
Unidentified speaker (UNKNOWN): way to uh to Wall
5:34
Unidentified speaker (speaker_3): Street. And and
5:35
Unidentified speaker (UNKNOWN): my path was
5:36
Unidentified speaker (speaker_3): was
5:36
Unidentified speaker (UNKNOWN): pretty
5:37
Unidentified speaker (speaker_2): interesting.
5:37
Unidentified speaker (UNKNOWN): I I happened to be
5:39
Unidentified speaker (speaker_3): looking for an apartment in Midtown
5:41
Unidentified speaker (UNKNOWN): because there
5:42
Unidentified speaker (speaker_3): weren't very
5:42
Unidentified speaker (UNKNOWN): many places you
5:43
Unidentified speaker (speaker_3): could find
5:43
Unidentified speaker (UNKNOWN): an apartment that you could
5:44
Unidentified speaker (speaker_3): afford coming
5:45
Unidentified speaker (speaker_2): out
5:45
Unidentified speaker (UNKNOWN): of grad
5:46
Unidentified speaker (speaker_3): school.
5:47
Unidentified speaker (UNKNOWN): And I was
5:47
Unidentified speaker (speaker_3): walking behind the JP Morgan building on Lexington.
5:50
Unidentified speaker (UNKNOWN): And I'm not going to mention the name of who
5:52
Unidentified speaker (speaker_2): walked up,
5:53
Unidentified speaker (UNKNOWN): you know,
5:53
Unidentified speaker (speaker_2): walked out of the building because he's a publicly traded CEO now.
5:56
Unidentified speaker (UNKNOWN): But it was
5:57
Unidentified speaker (speaker_2): a classmate of mine who it was a few years ahead of me.
5:59
Unidentified speaker (UNKNOWN): Um, And he
6:00
Unidentified speaker (speaker_2): stepped out of the building and I kind of looked at him and said, Hey. And he said, Hey, Dave, how you doing?
6:05
Unidentified speaker (UNKNOWN): And
6:05
Unidentified speaker (speaker_2): I said, uh,
6:06
Unidentified speaker (UNKNOWN): how
6:07
Unidentified speaker (speaker_2): do I get in there?
6:09
Unidentified speaker (UNKNOWN): And he
6:09
Unidentified speaker (speaker_2): basically, you know, it was a it was a it was a pretty funny uh uh path from there. He said, give me a call, let's grab a few beers. And he gave he basically laid out his his his pathway for me.
6:18
Unidentified speaker (UNKNOWN): But
6:18
Unidentified speaker (speaker_2): it really was me just bombing my resume out to a bunch of people.
6:22
Unidentified speaker (UNKNOWN): And just
6:23
Unidentified speaker (speaker_2): by happenstance, uh a team at Bank of America was looking on the biotech side. And then from there, I kind of jumped into Wall Street and was on the sell side and was there for about seven years before jumping over to the buy
6:33
Unidentified speaker (UNKNOWN): side.
6:34
Unidentified speaker (speaker_2): How does your training and the discipline that you
6:39
Unidentified speaker (UNKNOWN): got
6:40
Unidentified speaker (speaker_2): as a researcher lend itself to picking stocks?
6:45
Unidentified speaker (UNKNOWN): Yeah, so um, I guess a few things. You could talk
6:47
Unidentified speaker (speaker_2): specifically about healthcare,
6:49
Unidentified speaker (UNKNOWN): you know, where it's
6:50
Unidentified speaker (speaker_2): probably easier to understand. And
6:51
Unidentified speaker (UNKNOWN): then then there's
6:53
Unidentified speaker (speaker_2): the other part,
6:53
Unidentified speaker (UNKNOWN): which I
6:53
Unidentified speaker (speaker_2): think is a little
6:54
Unidentified speaker (UNKNOWN): bit
6:54
Unidentified speaker (speaker_2): more maybe qualitative
6:55
Unidentified speaker (UNKNOWN): and uh in in
6:57
Unidentified speaker (speaker_2): terms of thinking.
6:58
Unidentified speaker (UNKNOWN): But on the
6:59
Unidentified speaker (speaker_2): healthcare side
6:59
Unidentified speaker (UNKNOWN): for picking stocks, I think
7:02
Unidentified speaker (speaker_2): understanding
7:03
Unidentified speaker (UNKNOWN): science and
7:04
Unidentified speaker (speaker_2): medicine,
7:05
Unidentified speaker (UNKNOWN): what
7:05
Unidentified speaker (speaker_2): I've learned
7:06
Unidentified speaker (UNKNOWN): in
7:06
Unidentified speaker (speaker_2): grad school is
7:07
Unidentified speaker (UNKNOWN): really just understanding a
7:08
Unidentified speaker (speaker_2): fundamental language
7:09
Unidentified speaker (UNKNOWN): and
7:09
Unidentified speaker (speaker_2): being able
7:10
Unidentified speaker (UNKNOWN): to speak
7:10
Unidentified speaker (speaker_2): that language.
7:11
Unidentified speaker (UNKNOWN): Um so
7:12
Unidentified speaker (speaker_2): it makes more complex sub subjects. like like science and healthcare a little bit more easy to understand and and translate to to an investment idea.
7:21
Unidentified speaker (UNKNOWN): So
7:21
Unidentified speaker (speaker_2): I think from that standpoint it puts a little bit of a leg ahead there, just to be able to understand, you know, the basics of
7:27
Unidentified speaker (UNKNOWN): um of
7:28
Unidentified speaker (speaker_2): science, be able to speak that language, understand what's going on, maybe call BS a little bit faster than others.
7:34
Unidentified speaker (UNKNOWN): In
7:34
Unidentified speaker (speaker_2): terms of everything else, I think it's more the analytical process. And that's probably what you learn the most as a scientist. I think that's more the qualitative side, or at least I'm speaking the qualitative side here. But for me, it's it's the training that I got undergrad and grad school, learning how to think, learning how to analyze things and applying that
7:53
Unidentified speaker (UNKNOWN): in
7:53
Unidentified speaker (speaker_2): a rigorous fashion to uh picking picking investment And ideas. Um And I think the other thing that science teaches you is to be a skeptic. So, you know, that's the a good starting point for an investor is not to believe everything that you see and really dig in to make sure that you're headed in the right direction.
8:09
Unidentified speaker (UNKNOWN): Can
8:10
Unidentified speaker (speaker_2): you take us through a representative position and just uh how you think about
8:15
Unidentified speaker (UNKNOWN): uh
8:15
Unidentified speaker (speaker_2): the opportunity, how you think about the risks, that sort of stuff?
8:20
Unidentified speaker (UNKNOWN): Yeah. So
8:21
Unidentified speaker (speaker_2): maybe we'll think about
8:23
Unidentified speaker (UNKNOWN): um
8:24
Unidentified speaker (UNKNOWN): we'll
8:24
Unidentified speaker (speaker_2): think about a position that we have right now.
8:27
Unidentified speaker (UNKNOWN): um on the
8:28
Unidentified speaker (speaker_2): biotech side or biopharmacide and small cap.
8:31
Unidentified speaker (UNKNOWN): And uh
8:32
Unidentified speaker (speaker_2): that's mirror and pharmaceuticals. And I think the reason I bring that one up is it
8:36
Unidentified speaker (speaker_3): probably speaks pretty well about the types of names we look for
8:41
Unidentified speaker (UNKNOWN): in
8:41
Unidentified speaker (speaker_3): small tech small cap uh you know, biotech. You know, as a quality growth manager it it
8:46
Unidentified speaker (UNKNOWN): um
8:48
Unidentified speaker (UNKNOWN): as
8:48
Unidentified speaker (speaker_3): as a quality growth manager you but you probably start to wonder like how does how does small how does biotech fit into the portfolio?
8:55
Unidentified speaker (UNKNOWN): Um
8:56
Unidentified speaker (speaker_3): when a lot of times these companies don't have a real business, they're burning cash,
9:01
Unidentified speaker (UNKNOWN): um, there's a lot
9:02
Unidentified speaker (speaker_3): of idiosyncratic risk to them,
9:04
Unidentified speaker (UNKNOWN): a lot of binary risk. Um so the way that we've designed uh defined quality, at least in small, And small
9:09
Unidentified speaker (speaker_2): to mid-cap
9:10
Unidentified speaker (UNKNOWN): biotech, is uh looking for for companies that are a little bit further down. the
9:15
Unidentified speaker (speaker_2): developmental
9:16
Unidentified speaker (UNKNOWN): stage. So if you're thinking about the drug development cycles, usually go through phase one, phase two, phase three. When you think about risks to
9:25
Unidentified speaker (speaker_3): getting
9:26
Unidentified speaker (UNKNOWN): a drug approved, um, starting pre-phase one,
9:29
Unidentified speaker (speaker_2): like a
9:30
Unidentified speaker (UNKNOWN): you know,
9:30
Unidentified speaker (speaker_2): when a when a drug just gets into the clinic, it's a single-digit chance of actually becoming a marketed product. So you can understand there's a lot of risk there.
9:37
Unidentified speaker (UNKNOWN): But
9:37
Unidentified speaker (speaker_2): once you get past phase two, you know. the risks get a little bit better, or you start to look at something you know greater than 50-50. So it's a little bit more than a coin flip. So we start when we look at these biotech companies, we start at like the phase two stage. So we're thinking about companies that are a little bit past like the early stage developmental risk and have had shown some proof of concept. But what we really do is lean towards
9:57
Unidentified speaker (speaker_2): companies that are at commercial stage or or already commercial or about to become commercial. And Miriam is a company that kind of spans the hybrid. They have a business where they have a number of rare liver disease assets.
10:13
Unidentified speaker (UNKNOWN): The
10:13
Unidentified speaker (speaker_2): company is going to sell about 700 plus million dollars of sales this year in their in their marketed franchise. So it's an example of a company that is a real business. We believe they have a very good management team. They've built their business. on acquisition by acquiring a bunch of assets that have come out of pharma. The CEO,
10:33
Unidentified speaker (speaker_2): CFO, and chief commercial officers, all the guys on that management team are very good and been very good at identifying assets and not overpaying for them, bringing them in-house and being able to market them. And what Miriam Miriam has uh uh done is they've built a solid commercial. business and have a bunch of shots on gold that can drive
10:53
Unidentified speaker (speaker_2): upside from
10:54
Unidentified speaker (UNKNOWN): here. Um, and
10:55
Unidentified speaker (speaker_2): that's why we we like that company. And um
10:57
Unidentified speaker (UNKNOWN): this year
10:58
Unidentified speaker (speaker_2): we've seen
10:59
Unidentified speaker (UNKNOWN): uh
10:59
Unidentified speaker (speaker_2): the company
11:01
Unidentified speaker (UNKNOWN): do a lot of great things. Um, they
11:03
Unidentified speaker (speaker_3): presented
11:04
Unidentified speaker (UNKNOWN): data for
11:04
Unidentified speaker (speaker_3): some assets that
11:05
Unidentified speaker (speaker_2): they
11:05
Unidentified speaker (speaker_3): brought
11:05
Unidentified speaker (speaker_2): in-house that are uh in
11:07
Unidentified speaker (speaker_3): other rare liver
11:08
Unidentified speaker (UNKNOWN): diseases
11:08
Unidentified speaker (speaker_2): like
11:08
Unidentified speaker (UNKNOWN): uh
11:08
Unidentified speaker (speaker_3): PSC
11:09
Unidentified speaker (UNKNOWN): and
11:09
Unidentified speaker (speaker_3): PBC.
11:10
Unidentified speaker (speaker_2): They have this drug called
11:11
Unidentified speaker (speaker_3): Wolixabac that's
11:12
Unidentified speaker (UNKNOWN): in phase
11:13
Unidentified speaker (speaker_2): two,
11:13
Unidentified speaker (speaker_3): phase three right now for about. both of those indications.
11:16
Unidentified speaker (speaker_2): They presented
11:17
Unidentified speaker (UNKNOWN): PSC data at a
11:18
Unidentified speaker (speaker_2): big liver meeting
11:19
Unidentified speaker (UNKNOWN): that
11:19
Unidentified speaker (speaker_2): we were at in Europe earlier in the year. And it was a very striking,
11:23
Unidentified speaker (UNKNOWN): it was
11:24
Unidentified speaker (speaker_2): a really striking experience for us as we were sitting in the audience watching the pivotal data be presented and see just the reaction from the community and also some of the patient advocacy groups that were there. And what we realized was this comfort. company was developing really the first potential treatment for PSC. The unmet medical
11:44
Unidentified speaker (speaker_2): need was very clear and this could be you know a 20,000 patient
11:47
Unidentified speaker (UNKNOWN): market opportunity that could start for them next year. On
11:49
Unidentified speaker (speaker_2): top of that,
11:50
Unidentified speaker (UNKNOWN): they're moving through uh
11:53
Unidentified speaker (speaker_2): trial, trial
11:53
Unidentified speaker (UNKNOWN): readouts in PBC, which is an even bigger
11:56
Unidentified speaker (speaker_2): indication
11:56
Unidentified speaker (UNKNOWN): where
11:57
Unidentified speaker (speaker_2): there's
11:57
Unidentified speaker (UNKNOWN): less
11:57
Unidentified speaker (speaker_2): clinical
11:58
Unidentified speaker (UNKNOWN): risk because the mechanism of the drug is
12:00
Unidentified speaker (speaker_2): has already been
12:00
Unidentified speaker (UNKNOWN): approved
12:01
Unidentified speaker (speaker_2): uh from from
12:01
Unidentified speaker (UNKNOWN): other companies. And
12:03
Unidentified speaker (speaker_2): then finally, um, they've
12:05
Unidentified speaker (UNKNOWN): continued to grow the
12:06
Unidentified speaker (speaker_2): pipeline by in licensing
12:08
Unidentified speaker (UNKNOWN): other
12:08
Unidentified speaker (speaker_2): assets
12:09
Unidentified speaker (UNKNOWN): and
12:09
Unidentified speaker (speaker_2): in relatively
12:10
Unidentified speaker (UNKNOWN): um smart
12:11
Unidentified speaker (speaker_2): with relatively smart financial decisions,
12:14
Unidentified speaker (UNKNOWN): um acquiring
12:15
Unidentified speaker (speaker_2): drugs like
12:16
Unidentified speaker (UNKNOWN): uh uh a drug for this indication
12:18
Unidentified speaker (speaker_2): FOP from
12:19
Unidentified speaker (UNKNOWN): from
12:19
Unidentified speaker (speaker_2): insight for a
12:20
Unidentified speaker (UNKNOWN): song
12:21
Unidentified speaker (speaker_2): and FOP is this weird indication
12:23
Unidentified speaker (UNKNOWN): where um
12:23
Unidentified speaker (speaker_2): soft tissues
12:25
Unidentified speaker (UNKNOWN): start
12:25
Unidentified speaker (speaker_2): ossifying so you start developing bone where
12:27
Unidentified speaker (UNKNOWN): you
12:27
Unidentified speaker (speaker_3): shouldn't
12:28
Unidentified speaker (UNKNOWN): develop bone. So
12:29
Unidentified speaker (speaker_2): they're doing these
12:30
Unidentified speaker (UNKNOWN): deals and
12:30
Unidentified speaker (speaker_3): bringing in
12:31
Unidentified speaker (UNKNOWN): these assets. And that
12:32
Unidentified speaker (speaker_2): asset that
12:32
Unidentified speaker (UNKNOWN): they just brought
12:33
Unidentified speaker (speaker_3): in was approved,
12:33
Unidentified speaker (UNKNOWN): you know,
12:34
Unidentified speaker (speaker_3): a few months after
12:34
Unidentified speaker (speaker_2): they acquired it. $200 million
12:36
Unidentified speaker (speaker_3): opportunity
12:37
Unidentified speaker (UNKNOWN): that
12:37
Unidentified speaker (speaker_3): they basically
12:38
Unidentified speaker (speaker_2): paid,
12:38
Unidentified speaker (UNKNOWN): you know,
12:38
Unidentified speaker (speaker_2): something less than $100 million after
12:40
Unidentified speaker (UNKNOWN): you after
12:41
Unidentified speaker (speaker_2): you tie
12:41
Unidentified speaker (UNKNOWN): in all the all the milestones. So
12:45
Unidentified speaker (UNKNOWN): the way we think about this kind
12:47
Unidentified speaker (speaker_3): of
12:47
Unidentified speaker (UNKNOWN): a company is we see that they have uh a pretty strong commercial business that's been growing pretty readily. It's been a beat and raise year for them. And we're
12:56
Unidentified speaker (speaker_3): taking
12:57
Unidentified speaker (UNKNOWN): risk in the pipeline, but there's a fallback because they have a real
13:01
Unidentified speaker (speaker_3): business.
13:02
Unidentified speaker (UNKNOWN): And we know that the
13:04
Unidentified speaker (speaker_3): management team understands
13:05
Unidentified speaker (UNKNOWN): risk, is able to take assets in-house, but it's a diversified pipeline and they're going to continue, continue to do deals knowing that everything's not going to hit, everything's not going to be perfect. So I don't know if that fully answered the question, but it kind of gives like a span of types of companies we look for. We like later stage businesses. We're not afraid of of of clinical trial risk.
13:25
Unidentified speaker (UNKNOWN): We really look for good management teams and we want to see continued execution.
13:29
Unidentified speaker (speaker_0): And what do you think what is the
13:31
Unidentified speaker (UNKNOWN): what is
13:31
Unidentified speaker (speaker_0): what does the market get wrong on these? Like why would why are they consistently mispriced enough to to keep a full portfolio of them kind of going all the
13:41
Unidentified speaker (UNKNOWN): time? You mean why why why can't you have just a full portfolio of biotech names or well
13:47
Unidentified speaker (speaker_0): no more like um
13:48
Unidentified speaker (UNKNOWN): you know
13:49
Unidentified speaker (speaker_0): the market's pretty good often at at handicapping
13:53
Unidentified speaker (UNKNOWN): you know
13:53
Unidentified speaker (speaker_0): upside and downside
13:55
Unidentified speaker (UNKNOWN): of
13:55
Unidentified speaker (speaker_0): of these kind of
13:56
Unidentified speaker (UNKNOWN): you know
13:56
Unidentified speaker (speaker_0): random events that
13:58
Unidentified speaker (UNKNOWN): if
13:58
Unidentified speaker (speaker_0): from the outside of a novice, you know, uh biotech investor looks often like kind of logical lottery tickets, like you're just hoping one of these cashes in and you get a big payday for it. Um
14:08
Unidentified speaker (UNKNOWN): but
14:08
Unidentified speaker (speaker_0): yeah why does and I guess later stage obviously looks a little bit more like actual real business development and less like uh you know sci fi projects or or just uh you know shots on goal like that. But
14:19
Unidentified speaker (UNKNOWN): but
14:19
Unidentified speaker (speaker_0): there must be something that the market does consistently get wrong in order for there to be an opportunity for you to to earn an outsized return.
14:27
Unidentified speaker (UNKNOWN): Yeah, I think I think there's a a couple things. With a name like Miram, um
14:34
Unidentified speaker (UNKNOWN): one, uh
14:37
Unidentified speaker (UNKNOWN): with the indications that they're in,
14:38
Unidentified speaker (speaker_3): like
14:39
Unidentified speaker (UNKNOWN): these small rare disease indications,
14:41
Unidentified speaker (speaker_2): I think
14:41
Unidentified speaker (UNKNOWN): there's
14:41
Unidentified speaker (speaker_2): always an element
14:42
Unidentified speaker (UNKNOWN): of upside for how big there
14:43
Unidentified speaker (speaker_3): could be an element of upside for
14:44
Unidentified speaker (UNKNOWN): how big
14:45
Unidentified speaker (speaker_3): the patient population
14:46
Unidentified speaker (UNKNOWN): is. Um and in in their case, the the rare
14:50
Unidentified speaker (speaker_3): disease commercial. franchise
14:51
Unidentified speaker (UNKNOWN): that
14:51
Unidentified speaker (speaker_2): they
14:52
Unidentified speaker (UNKNOWN): have right now was probably underinvested from the
14:54
Unidentified speaker (speaker_2): company they they
14:56
Unidentified speaker (UNKNOWN): the
14:56
Unidentified speaker (speaker_2): companies
14:56
Unidentified speaker (UNKNOWN): that they
14:57
Unidentified speaker (speaker_2): acquired it from. So they were able to really streamline the sales process, identify patients, get their drugs out to doctors. So I think that's one element where
15:06
Unidentified speaker (UNKNOWN): you
15:07
Unidentified speaker (speaker_2): could produce some outsized return. That's not that's not always going to work because eventually the market does catch on and sees that you're able to identify patients and you know that that works for maybe a couple quarters. But I think another place where um where there always is
15:22
Unidentified speaker (speaker_2): a level of uh of of unknown is just anything tied to clinical development. I
15:27
Unidentified speaker (UNKNOWN): think
15:27
Unidentified speaker (speaker_2): that is like one area where there is true idiosyncratic risk in the market. Biology is inherently unpredictable, and you really don't know what's going what's going to work. Um,
15:38
Unidentified speaker (UNKNOWN): so I think.
15:39
Unidentified speaker (speaker_2): that adds like you know a real opportunity um for you to take educated risks on things. And and a company like
15:47
Unidentified speaker (UNKNOWN): like
15:47
Unidentified speaker (speaker_2): this is not always going to have that risk or have the upside fully baked in. So there's always going to be some level of upside unless it's something that is truly easy to call and those are the instances This is where you see a trial readout and the stock doesn't do anything more, or it's positive and it goes down. Well those those are obvious that everybody knows. Um, but I think a lot of times with with these rare indications where there isn't a lot of
16:07
Unidentified speaker (speaker_2): precedent data before that, um, it makes it
16:11
Unidentified speaker (UNKNOWN): a
16:11
Unidentified speaker (speaker_2): little harder to predict that you get paid for taking that kind of risk.
16:16
Unidentified speaker (UNKNOWN): So I
16:17
Unidentified speaker (speaker_2): don't know if that fully answered your question.
16:19
Unidentified speaker (speaker_0): Okay. When I sell my business, I want the best tax and investment advice. I want to help my kids, and I want to give back to the community. Ooh, then it's the vacation of a lifetime. I wonder if my out of office has a forever setter.
16:34
Unidentified speaker (speaker_1): An IG Private Wealth Advisor creates the clarity you need with plans that harmonize your business, your family, and your dreams. Get financial advice that puts you at the center. Find your advisor at IGPrivatewealth.com.
16:49
Unidentified speaker (UNKNOWN): The
16:49
Unidentified speaker (speaker_2): sports calendar is on fire in the sports. and the score bet has you covered with breaking news and betting seamlessly connected. Every play, every stat, every score, giving you the tools you need to bet confidently. Born in the North, built for you. The Score Bet, Canada Sportsbook. Please play responsibly, 18 years or older.
17:05
Unidentified speaker (speaker_3): If gambling is affecting your mental health or well-being, help is available. In Alberta, call or text 211 two one one or visit ab.211.ca. Standard message and data rates may apply.
17:21
Unidentified speaker (UNKNOWN): Yeah,
17:22
Unidentified speaker (speaker_0): I think it's just maybe the uh people don't like to hold uncertainty and therefore things can get mispriced, like the the odds on offer uh
17:32
Unidentified speaker (UNKNOWN): if
17:33
Unidentified speaker (speaker_0): we invert from the price backwards of what the business could turn into, um
17:37
Unidentified speaker (UNKNOWN): that
17:38
Unidentified speaker (speaker_0): that level of ambiguity uh could scare people off of it.
17:42
Unidentified speaker (UNKNOWN): Yeah, yeah, and there's there's always like nothing is nothing is perfect. You know, there's always an element of regulatory risk as well, then there's commercial risk after that. So you're you know, the the the earlier stage the asset or the earlier stage the thing you're gambling on. You have the the risk of the clinical trial, the risk of getting the drug approved, the risk of actually executing commercially, and those things compound,
18:02
Unidentified speaker (UNKNOWN): right?
18:03
Unidentified speaker (UNKNOWN): This
18:03
Unidentified speaker (speaker_2): is uh this is a traditional, more more traditional value podcast. So we we tend to be looking at uh things that are a little bit more established. And then if we're looking at growth where sort of the growth is a little bit more manifest, you know, we can see that there are years of growth. This seems like it's it's reasonably early stage. Is it something more like is it l s akin to v venture capital? Is
18:23
Unidentified speaker (speaker_2): it is it that early stage?
18:26
Unidentified speaker (UNKNOWN): Well Uh you mean investing in in
18:29
Unidentified speaker (UNKNOWN): how how how so uh so
18:31
Unidentified speaker (speaker_2): yeah, just just in terms of like you you and
18:33
Unidentified speaker (speaker_0): maybe the re return profile, does that look very spiky, like you know, it's very power law driven? That's that's what I mean.
18:40
Unidentified speaker (UNKNOWN): Yeah, I I think so. Um it it really depends on it really depends on the stage of company that you're you're investing in. Like a company like I just described, you're not gonna have you're not gonna have the,
18:54
Unidentified speaker (UNKNOWN): you're not gonna have an immediate multi-bagger return on something because they have an existing business, you're already pricing in value for that business,
19:02
Unidentified speaker (speaker_0): then you're having uh upside returns on top of that that'll get
19:05
Unidentified speaker (UNKNOWN): you, you know,
19:06
Unidentified speaker (speaker_0): hopefully double digit percentages on data readouts, drug approvals, et cetera. Where you start to get multi-bagger multi bagger type, you know, log step up. or really step up returns are when you're investing an earlier stage or there's there's a takeout. But that there is an element of that when you're investing in small cap healthcare. Um, I think because when you think
19:26
Unidentified speaker (speaker_0): about these things, they're long duration assets. Clinical trials can
19:29
Unidentified speaker (UNKNOWN): take years
19:30
Unidentified speaker (speaker_0): and years to read
19:31
Unidentified speaker (UNKNOWN): out.
19:31
Unidentified speaker (speaker_0): So the the value proposition could
19:33
Unidentified speaker (UNKNOWN): be
19:33
Unidentified speaker (speaker_0): you sit flat for a while
19:35
Unidentified speaker (UNKNOWN): and you have a step
19:35
Unidentified speaker (speaker_0): up or a step down based on something that reads
19:37
Unidentified speaker (UNKNOWN): out, or if a company
19:39
Unidentified speaker (speaker_0): comes in to
19:40
Unidentified speaker (UNKNOWN): acquire,
19:40
Unidentified speaker (speaker_0): that's when you could see like
19:41
Unidentified speaker (UNKNOWN): really
19:41
Unidentified speaker (speaker_0): major,
19:42
Unidentified speaker (UNKNOWN): uh, major
19:43
Unidentified speaker (speaker_0): upside returns.
19:44
Unidentified speaker (UNKNOWN): So
19:45
Unidentified speaker (speaker_0): when we think about investing in these kinds of businesses, obviously
19:48
Unidentified speaker (UNKNOWN): we're we're a uh a
19:51
Unidentified speaker (speaker_0): long-only small cap
19:53
Unidentified speaker (UNKNOWN): uh, you know, the
19:54
Unidentified speaker (speaker_0): fund, my fund is a long-only small cap
19:57
Unidentified speaker (UNKNOWN): uh
19:57
Unidentified speaker (speaker_0): growth
19:57
Unidentified speaker (UNKNOWN): product. We don't want to have this
19:59
Unidentified speaker (speaker_3): be a purely binary
20:01
Unidentified speaker (UNKNOWN): um. or
20:03
Unidentified speaker (speaker_3): purely binary type
20:04
Unidentified speaker (UNKNOWN): uh uh uh
20:05
Unidentified speaker (speaker_3): product.
20:06
Unidentified speaker (speaker_0): So we balance our portfolio
20:08
Unidentified speaker (UNKNOWN): with some um some
20:10
Unidentified speaker (speaker_3): higher risk assets, but a
20:12
Unidentified speaker (speaker_0): lot
20:12
Unidentified speaker (speaker_3): more
20:13
Unidentified speaker (speaker_0): of
20:13
Unidentified speaker (UNKNOWN): our
20:13
Unidentified speaker (speaker_0): healthcare
20:14
Unidentified speaker (speaker_3): positions
20:14
Unidentified speaker (speaker_0): have the
20:15
Unidentified speaker (speaker_3): look
20:15
Unidentified speaker (speaker_0): and
20:15
Unidentified speaker (speaker_3): feel of a mirror
20:16
Unidentified speaker (UNKNOWN): where you
20:17
Unidentified speaker (speaker_3): can get
20:17
Unidentified speaker (UNKNOWN): um uh you
20:19
Unidentified speaker (speaker_3): can get both upside from binary events
20:22
Unidentified speaker (speaker_0): and
20:22
Unidentified speaker (UNKNOWN): also play
20:23
Unidentified speaker (speaker_3): a commercial business
20:24
Unidentified speaker (UNKNOWN): that's going to be steady and hopefully the company will continue to deploy. capital eff efficiently. So not exactly value investing, not exactly momentum growth investing. It's a little bit sort of in between. How
20:36
Unidentified speaker (speaker_2): do you think about position sizing
20:38
Unidentified speaker (UNKNOWN): uh
20:39
Unidentified speaker (speaker_2): diversification concentration when you're sizing positions like this?
20:43
Unidentified speaker (UNKNOWN): Yeah, it's a it's a a very good question. It's a key element of how we uh how we um of how we manage a risk. Uh for a
20:51
Unidentified speaker (speaker_3): company like this, some we're willing to make it a a bigger position. It can be a top 10 position in our portfolio just because they have such a big commercial business that showing growth worse comes to worse, they can shut their entire developmental pipeline down and be a profitable business right now. So that's something that we're a lot more comfortable leaning into. But if you're talking
21:11
Unidentified speaker (speaker_3): about um an earlier stage biotech company, like if we do take if we do take risk on
21:18
Unidentified speaker (speaker_3): if we do take risk on a phase two, phase three binary event, that's got to be a lot smaller. So just thinking about pure sizing, totally happy making a company like Miram,
21:31
Unidentified speaker (UNKNOWN): you know,
21:32
Unidentified speaker (speaker_3): greater than 100 basis points of active weight, you know, talking about maybe 150 up to 200, that's a comfortable place for us to be. But if you're talking about something that we're walking into pure hero zero kind of territory where they may have a few
21:45
Unidentified speaker (UNKNOWN): assets in development, but the reality of it is the value hinges on a lead asset we know when a binary event's coming up, then 25 to 50 basis points of active weight is the kind of risk we're willing to take for you Or know 100% return potentially on that, but knowing that we could lose um, you know, a good majority of our of our. active position. So the
22:05
Unidentified speaker (speaker_2): portfolio tends to be fairly diversified.
22:06
Unidentified speaker (UNKNOWN): That that's like s
22:08
Unidentified speaker (speaker_2): 75, 100 positions plus more than that.
22:11
Unidentified speaker (UNKNOWN): Yeah.
22:14
Unidentified speaker (UNKNOWN): But
22:14
Unidentified speaker (speaker_3): uh yeah, we say, you know, between we run between I'd say 75 and 100 positions
22:19
Unidentified speaker (UNKNOWN): um uh
22:20
Unidentified speaker (speaker_3): in in the small cap Kaplan. land.
22:22
Unidentified speaker (UNKNOWN): And how do you
22:23
Unidentified speaker (speaker_2): keep track of
22:24
Unidentified speaker (UNKNOWN): uh
22:24
Unidentified speaker (speaker_2): that number of positions?
22:26
Unidentified speaker (UNKNOWN): Um well
22:27
Unidentified speaker (speaker_3): we have a we have a team. Uh so it's it's not it's not just me. Uh thankfully we've we've we've got a team of portfolio managers and a team of analysts that cover uh that cover the sector uh sectors. Um in healthcare
22:40
Unidentified speaker (UNKNOWN): we have we have three uh we have a three-man team
22:42
Unidentified speaker (speaker_3): that uh
22:43
Unidentified speaker (UNKNOWN): that
22:43
Unidentified speaker (speaker_3): covers
22:43
Unidentified speaker (UNKNOWN): that splits healthcare
22:44
Unidentified speaker (speaker_3): apart.
22:45
Unidentified speaker (UNKNOWN): Um so we're able to cover a lot of
22:46
Unidentified speaker (speaker_3): ground that
22:47
Unidentified speaker (UNKNOWN): way. Uh and then we have uh uh
22:49
Unidentified speaker (speaker_3): teams
22:49
Unidentified speaker (UNKNOWN): that cover the
22:50
Unidentified speaker (speaker_3): other subsequent.
22:50
Unidentified speaker (UNKNOWN): subsectors.
22:51
Unidentified speaker (speaker_3): So teams
22:51
Unidentified speaker (UNKNOWN): that cover industrials,
22:53
Unidentified speaker (speaker_3): we
22:53
Unidentified speaker (UNKNOWN): have consumer, uh uh
22:55
Unidentified speaker (speaker_3): energy, um,
22:56
Unidentified speaker (UNKNOWN): obviously
22:57
Unidentified speaker (speaker_3): tech.
22:57
Unidentified speaker (UNKNOWN): Uh so
22:58
Unidentified speaker (speaker_3): it's
22:58
Unidentified speaker (UNKNOWN): it's a
22:58
Unidentified speaker (speaker_3): it's
22:58
Unidentified speaker (UNKNOWN): a team approach. Um so it's
23:01
Unidentified speaker (speaker_3): not
23:01
Unidentified speaker (UNKNOWN): one man
23:02
Unidentified speaker (speaker_3): manning manning everything.
23:05
Unidentified speaker (UNKNOWN): One
23:05
Unidentified speaker (speaker_0): of the uh especially tech sector with with so much of the economics kind of on the cum of you know development and and
23:12
Unidentified speaker (UNKNOWN): uh
23:12
Unidentified speaker (speaker_0): getting something through FDA. Does that make it especially sensitive to the cost of capital? So if interest rates go up, you you feel that?
23:21
Unidentified speaker (UNKNOWN): Yeah, yeah. It's a it's a it's a good question, um and a and and a good observation. But uh but yeah I'd say anyone that follows that file follows biotech or or or anything high high-tech tech where there's long
23:34
Unidentified speaker (speaker_0): duration assets, if there's an inverse correlation to to uh to yields. Um
23:39
Unidentified speaker (UNKNOWN): so
23:39
Unidentified speaker (speaker_0): as you see the cost of capital go up, um there's there's a little bit more pressure on uh there's a little bit more pressure on those types of assets. I think now
23:48
Unidentified speaker (UNKNOWN): um there
23:49
Unidentified speaker (speaker_0): is a little dislocation with that.
23:52
Unidentified speaker (UNKNOWN): Um
23:53
Unidentified speaker (speaker_0): we've seen
23:54
Unidentified speaker (UNKNOWN): uh
23:55
Unidentified speaker (speaker_0): as we've seen as we've seen rates go up recently it's also coincided with you know some fears around I guess the AI build build-out out AI spend
24:03
Unidentified speaker (speaker_0): So it's caused money to come flying out of other areas. And one of the safe havens would be to move in healthcare. So I think there's been a little bit of a reprieve in healthcare. But there is a bifurcation there as well where you'll see
24:17
Unidentified speaker (speaker_0): the commercial businesses in aggregate, that you know, outside of you know, the binary events. For if a binary events happens, stocks move idiosyncratically up. or down, irrespective of what the tenure
24:28
Unidentified speaker (UNKNOWN): is doing, obviously. But um what what you'll see is is a preference and a
24:33
Unidentified speaker (speaker_2): bifurcation between commercial
24:35
Unidentified speaker (UNKNOWN): stage and developmental stage
24:36
Unidentified speaker (speaker_2): companies where
24:36
Unidentified speaker (UNKNOWN): the
24:37
Unidentified speaker (speaker_2): commercial stage companies
24:37
Unidentified speaker (UNKNOWN): will will be favored in that higher rate environment when there's money moves like this. Yeah,
24:42
Unidentified speaker (speaker_2): that that's that was going to be my question. Does it healthcare seems to be a little bit defensive and so it trails when the market's very
24:49
Unidentified speaker (UNKNOWN): very
24:49
Unidentified speaker (speaker_2): uh in a boom and then it seems to look a little bit better when the market's a little bit uh under a little bit
24:55
Unidentified speaker (speaker_0): more pressure. But the the question that I had
24:58
Unidentified speaker (UNKNOWN): was from
24:59
Unidentified speaker (speaker_0): the outside, biotech seems to be a little bit cyclical in the sense
25:02
Unidentified speaker (UNKNOWN): that there
25:03
Unidentified speaker (speaker_0): do there are these occasions,
25:05
Unidentified speaker (UNKNOWN): um
25:06
Unidentified speaker (speaker_0): rarely but regularly, where the whole sector seems to trade at a discount to net cash.
25:12
Unidentified speaker (UNKNOWN): Is
25:12
Unidentified speaker (speaker_0): there um like free pipelines is the thing?
25:15
Unidentified speaker (UNKNOWN): Yeah you
25:15
Unidentified speaker (speaker_0): get these you get these occasional bites of the cherry where it looks like you're getting a a free hit, knowing that they're gonna spend the cash, but across the cohort you get some reasonable
25:23
Unidentified speaker (speaker_2): returns. Where are we in that in that cycle? Is that a fair characterization?
25:27
Unidentified speaker (speaker_0): Yeah, I mean it it is, I think when you're looking at uh um larger companies that have businesses, you can't make that generalization when you're looking in the in the cap range that that we look at on the small cap side. Maybe you could see a little bit more on the mid-cap side.
25:43
Unidentified speaker (UNKNOWN): But
25:43
Unidentified speaker (speaker_0): I'd say that in in general, there are,
25:47
Unidentified speaker (speaker_0): I'd say that it's
25:49
Unidentified speaker (UNKNOWN): I
25:49
Unidentified speaker (speaker_0): guess what I would say is when looking at biotech, you might not be seeing that right now, or biopharma, you know, might not be seeing that right now. But we were starting to see that in other areas like medical devices, which were trading at what seemed like historic loads lows on valuation, where you were discounting the businesses tremendously. You're definitely discounting any any uh
26:09
Unidentified speaker (speaker_0): upside. But I think what you're saying might apply more to some of the larger companies where
26:15
Unidentified speaker (UNKNOWN): um
26:16
Unidentified speaker (speaker_0): where you're not getting any pipeline value in some instances for for things. And you know, I to some extent I'd make that argument right now with with a with a mirror where you know that's what we're we're believing in. Like we could see. what's happening with the commercial business, but we think we're getting a pretty substantial discount on the pipeline that they've that they've built.
26:35
Unidentified speaker (UNKNOWN): Uh one subject that
26:36
Unidentified speaker (speaker_0): I've been particularly interested
26:37
Unidentified speaker (UNKNOWN): in recently is the rise of AI. And just the the gain of the
26:42
Unidentified speaker (speaker_0): only one, I think. Yeah, no, I haven't
26:44
Unidentified speaker (UNKNOWN): heard that
26:44
Unidentified speaker (speaker_0): one before.
26:45
Unidentified speaker (UNKNOWN): Is
26:45
Unidentified speaker (speaker_0): anyone else curious about this?
26:47
Unidentified speaker (speaker_2): The uh the the gains year over year are sort of a astonishing, but I'm guessing that that's really uh impactful in in biopharma.
26:56
Unidentified speaker (UNKNOWN): Yeah,
26:57
Unidentified speaker (speaker_2): what
26:57
Unidentified speaker (speaker_0): does AI mean for
26:59
Unidentified speaker (speaker_2): yeah
26:59
Unidentified speaker (speaker_0): for uh for biotech? I mean you hear lots of prognostications about
27:04
Unidentified speaker (UNKNOWN): uh
27:05
Unidentified speaker (speaker_0): biology becoming much more of an information science
27:08
Unidentified speaker (UNKNOWN): uh
27:09
Unidentified speaker (speaker_0): digital uh you know labs and all that kind of stuff.
27:13
Unidentified speaker (speaker_3): Yeah, I mean uh I look I I I I hold a lot of hope for for where
27:19
Unidentified speaker (speaker_3): AI is going to aid in in biopharma, drug discovery, treating disease and all the other things. And hopefully it doesn't put us all out of a job is the other the flip side, right?
27:30
Unidentified speaker (UNKNOWN): But
27:30
Unidentified speaker (speaker_3): I but I think you know the the the initial or the high level levels is that you know this idea that AI is going to be able to help us design drugs for undruggable or or
27:41
Unidentified speaker (UNKNOWN): um
27:41
Unidentified speaker (speaker_3): uncurable diseases.
27:44
Unidentified speaker (speaker_3): But I think what we've seen
27:46
Unidentified speaker (UNKNOWN): so
27:46
Unidentified speaker (speaker_3): far is like real efficiency on being able to design molecules faster,
27:53
Unidentified speaker (speaker_3): but not really, you know, a real impact on biology. And what I mean by that is you can see like a lot of productivity gains at the early end on the developmental side. And I think there's companies out
28:06
Unidentified speaker (UNKNOWN): there
28:06
Unidentified speaker (speaker_0): that have said,
28:07
Unidentified speaker (UNKNOWN): um,
28:08
Unidentified speaker (UNKNOWN): what
28:08
Unidentified speaker (speaker_0): we're seeing is uh, you know, time from from idea to
28:13
Unidentified speaker (UNKNOWN): uh
28:13
Unidentified speaker (speaker_0): to drug to be being able to put a drug in the clinic or developmental candidate or developing a uh developmental candidate has been really fast. Like these companies can do it in 17 months and be ready to start, you know, moving towards a clinical trial.
28:24
Unidentified speaker (UNKNOWN): So
28:24
Unidentified speaker (speaker_0): that's sped up. What we've also seen. is
28:30
Unidentified speaker (speaker_0): productivity gains at the phase one, phase two side. So when you're
28:33
Unidentified speaker (UNKNOWN): moving
28:33
Unidentified speaker (speaker_0): from phase one to phase
28:35
Unidentified speaker (UNKNOWN): two in drug
28:36
Unidentified speaker (speaker_0): development, really what you're doing is like sort
28:38
Unidentified speaker (UNKNOWN): of
28:38
Unidentified speaker (speaker_0): an initial proof of concept, the drug is hitting the target that you wanna see. And I think you've seen a lot more success. There's been some papers written on this that have shown AI has driven success rates up going from phase one to phase
28:50
Unidentified speaker (UNKNOWN): two.
28:51
Unidentified speaker (UNKNOWN): But what we
28:51
Unidentified speaker (speaker_0): haven't seen is like
28:53
Unidentified speaker (UNKNOWN): the
28:53
Unidentified speaker (speaker_0): success rates from phase two to phase three improve with those
28:57
Unidentified speaker (UNKNOWN): drugs. And that's
28:58
Unidentified speaker (speaker_0): really like the proof of biology.
29:00
Unidentified speaker (UNKNOWN): So
29:01
Unidentified speaker (speaker_3): phase
29:02
Unidentified speaker (speaker_0): two
29:02
Unidentified speaker (UNKNOWN): is
29:02
Unidentified speaker (speaker_0): the first point in
29:03
Unidentified speaker (speaker_3): time
29:03
Unidentified speaker (UNKNOWN): where
29:03
Unidentified speaker (speaker_3): you get proof of like, are you treating the diseased? Are you showing that you're having an impact on the disease?
29:09
Unidentified speaker (UNKNOWN): And
29:09
Unidentified speaker (speaker_3): we haven't seen an improvement there in in AI generated drugs. So efficient agenda. at generating efficient at generating the the you know a better molecule that attaches to a target, not efficient at actually improving the biology. So I think that's where the
29:24
Unidentified speaker (speaker_0): improvement needs to come
29:25
Unidentified speaker (UNKNOWN): from. So
29:26
Unidentified speaker (speaker_0): that's one
29:26
Unidentified speaker (speaker_3): thing.
29:27
Unidentified speaker (UNKNOWN): Um what do you think
29:28
Unidentified speaker (speaker_0): that is though? Just before
29:29
Unidentified speaker (UNKNOWN): we go back.
29:29
Unidentified speaker (speaker_3): I think biology is in inherently unpredictable and very complex, and we just haven't gotten we haven't gotten there yet. And I'm not saying that we won't. Um we just we just haven't gotten there yet. Um there's a lot of hope that it's that we're going to get there. I think if you look at uh if you look at um you know some of the companies that are really
29:49
Unidentified speaker (speaker_3): generating a lot of buzz that are spanning
29:53
Unidentified speaker (speaker_3): bioforma AI and and AI right
29:55
Unidentified speaker (UNKNOWN): now, I mean the first
29:56
Unidentified speaker (speaker_3): one that comes to mind is is like this. I
29:58
Unidentified speaker (UNKNOWN): think it's
29:58
Unidentified speaker (speaker_3): Isomorphic Labs, which
30:00
Unidentified speaker (UNKNOWN): is the
30:00
Unidentified speaker (speaker_3): Google Deep Mind
30:01
Unidentified speaker (UNKNOWN): CEO,
30:02
Unidentified speaker (speaker_3): Demosis. Demis Asabas, is the
30:04
Unidentified speaker (UNKNOWN): CEO of
30:04
Unidentified speaker (speaker_3): that company.
30:05
Unidentified speaker (UNKNOWN): And
30:05
Unidentified speaker (speaker_3): he um
30:07
Unidentified speaker (UNKNOWN): he
30:07
Unidentified speaker (speaker_3): uh he won the Nobel Prize uh for for basically being part of like the whole Alpha Fold project and really showing that you can use AI to predict protein structure.
30:17
Unidentified speaker (UNKNOWN): Um so
30:18
Unidentified speaker (speaker_3): there's been he's they've raised over $2 billion focused on
30:22
Unidentified speaker (speaker_0): the ability to really help develop drugs. So I think there's a lot of hope that that's that's going to happen. And maybe those are going to be the people that actually are able to translate
30:31
Unidentified speaker (UNKNOWN): um
30:32
Unidentified speaker (speaker_0): translate that that
30:34
Unidentified speaker (UNKNOWN): you
30:34
Unidentified speaker (speaker_0): know that that the biology and basically move to help AI be better at actually developing drugs. But we just we just haven't seen that yet. Another area that's that's that's interesting that we've seen with AI is um
30:50
Unidentified speaker (UNKNOWN): is the
30:50
Unidentified speaker (speaker_3): this idea of
30:51
Unidentified speaker (UNKNOWN): uh
30:52
Unidentified speaker (speaker_3): of of patient enrollment and patient selection, which is
30:54
Unidentified speaker (UNKNOWN): like
30:55
Unidentified speaker (speaker_3): surprisingly um
30:57
Unidentified speaker (UNKNOWN): you know an
30:58
Unidentified speaker (speaker_3): area that that needs help on in sort of the clinical trial drug development side. Like there's a lot of the like a large percentage of the phase two, phase three
31:08
Unidentified speaker (UNKNOWN): um
31:09
Unidentified speaker (speaker_3): trial halts are attributed to the inability to actually enroll the trial and select patients for it.
31:15
Unidentified speaker (speaker_3): So they've
31:16
Unidentified speaker (speaker_0): shown that AI has been able to remarkably help in terms of identifying and selecting patients for clinical trials. So that is one thing that's that's that's going, I think, that AI has been helping with and will continue to help with. But there was actually an interesting quote from I think the Lily CSO, which is like I guess when you think about the other thing, is like it
31:36
Unidentified speaker (speaker_0): takes so long to develop a drug. It could take like, I think. Sandy says it takes like 13 and a half, or they budget 13 and a half years to develop a drug. And less than half of that time is on the preclinical side, which we talk about, we talked already talked about like efficiency gains. And Sanafi's saying they want to cut that 13 and a half years by 40%,
31:53
Unidentified speaker (speaker_0): but only half of that's going to come from that preclinical side. You still have to figure out how to make the clinical side move faster. And then I go back to the Lily uh CSO comment that I want wanted to make, which is, you know, look, look, you know, there's nothing that AI can do to shrink like an Alzheimer's prevention trial that would take three and a half years to run to three weeks.
32:13
Unidentified speaker (speaker_0): There's nothing you could do about that. So there's got to be something else that that AI helps you figure out to like shrink. So set a lot there. I'll stop and let you guys jump back in.
32:24
Unidentified speaker (UNKNOWN): Yeah,
32:24
Unidentified speaker (speaker_2): that's fascinating. Let me just let me just give a quick shout out to everybody who's listening and uh then we'll do some veggies, give you, give you a little bit of a break.
32:32
Unidentified speaker (UNKNOWN): Um
32:32
Unidentified speaker (speaker_2): Brecken Rich, what's up? Bendigo, Victoria, early start for you, Hamish.
32:37
Unidentified speaker (UNKNOWN): Or
32:38
Unidentified speaker (speaker_2): late start for you. Lawrence, Kansas, Dead Cat Gully, New South Wales.
32:42
Unidentified speaker (UNKNOWN): Uh,
32:42
Unidentified speaker (speaker_2): not so bad these days, actually. We're out of the dead cat gully, I think. Valparaissa, Antwerp, Belgium, Snohomish, Toronto, Jupiter, Florida. Capavoga, Iceland, Bremerton, Havertown, Bellevue, Portsmouth, Prince George, Stuttgart, Germany, Hartford, Alabama, Gothenburg, Sweden, Bangalore,
33:01
Unidentified speaker (speaker_2): India, Guurney, Illinois, Clinton, Tennessee, Orlando, Florida, Mean Street, GX. Did I skip anybody over there? Sorry if I missed
33:10
Unidentified speaker (UNKNOWN): you.
33:11
Unidentified speaker (speaker_2): Uh Antwerp, Belgium, do I get you? Snohomish. All right. JT, got some veggies for us today.
33:18
Unidentified speaker (speaker_0): Yeah. Can't believe they're still tuning in from that far away.
33:22
Unidentified speaker (speaker_2): We appreciate it.
33:24
Unidentified speaker (speaker_0): So I I uh I recently reread uh Ed Weister's autobiography called No Shortcuts to the Top. Really fun book to read. Uh Ed is one of, if not the greatest American mountain climbers. Uh so let's set the scene here. It's May tw 2005. We're at the summit of Annaperna, and Ed looks at
33:44
Unidentified speaker (speaker_0): his watch and it's two o'clock, and he has one unbreakable rule. If he's not standing on the summit by two in the afternoon, he turns around, no matter what. And over the last 18 years at that point, he'd been chasing the 14 tallest mountains in the world, summiting them. And Annapurna was the last one on his list. Uh he reaches the top at the final minute, really, that he
34:04
Unidentified speaker (speaker_0): allowed himself. Let's go back to 1987. His first shot at an 8,000 meter peak, and it happened to be Mount Everest. So there's 8,000 there's 14 8,000 meter or higher peaks on the planet. So he gets to within a few hundred feet of the summit. And And you have to remember, he's been climbing for like month, two
34:24
Unidentified speaker (speaker_0): months at that point, right? Like you're making these base camps. it's like incredibly grueling work. Uh, and he runs into this really steep rock step right at the top. And they've used up all their ropes and other climbing gear getting this far. And the clouds are starting to build, and he could definitely climb up and make it up, but they'd struggle to get back down. So he turns around and never
34:44
Unidentified speaker (speaker_0): he doesn't get to the top. So he said afterwards that he was disappointed, obviously, but he's also proud. And he has a motto: getting to the top. is optional, getting down is mandatory.
34:54
Unidentified speaker (speaker_0): So Ed climbed 14 of the tallest peaks on Earth, all over 8,000 meters, all without oxygen, uh supplemental oxygen. And he was the first American to ever do that, and the fifth person ever. And it took him 31 expeditions to get to 21 summits over that size. And 10 times he went home empty-handed empty handed after months of working setting up these bases.
35:14
Unidentified speaker (speaker_0): base camps, training full time. Uh basically you couldn't have another job other than doing this. Uh just absolutely incredibly arduous physical uh physical uh expenditures to do this. And 10 times he got tantalizing tantalizing close to the top and then had to stop.
35:31
Unidentified speaker (UNKNOWN): Uh,
35:31
Unidentified speaker (speaker_0): but zero times did he not go home safely. So above eight 8,000 thousand meters, and you know, David, you can could probably help with some of the uh the science behind this, but they call that the death zone. And your body can't accl acclimatize to that level. And the first thing that goes is not really your legs, it's your judgment. Uh hypoxia makes you
35:51
Unidentified speaker (speaker_0): slow, stubborn, confident, uh, and probably the worst combination. So the most important decision of the climb, whether to turn around or to keep going, gets made by the dumbest version of you, basically. Uh so climbers have have a name for it. They
36:05
Unidentified speaker (UNKNOWN): call
36:05
Unidentified speaker (speaker_0): it summit fever. Most days the danger isn't really that rock step, it's it's the clock. Uh and for the clock,
36:13
Unidentified speaker (UNKNOWN): uh
36:13
Unidentified speaker (speaker_0): Ed's answer wasn't actually to use better judgment. It was no judgment at all. It was this very strict rule. Two o'clock. Number that he set at base Basecamp, camp, while the version of himself that wasn't in hypoxia, he had all the oxygen in his brain. Uh so, and that was basically he was trying to bind the impaired guy to the decision that the sober guy made. Uh so
36:33
Unidentified speaker (speaker_0): having this rule is one thing and following it a second time can be even harder. So in 1995, this guy Rob Hall, who was another talented American climber, was guiding a client named Doug Hanson on Everest. And Hansen got really close to the summit, but they had to turn around and go back. And he came home with unfinished business. A year later, he returned with Hall.
36:53
Unidentified speaker (speaker_0): And according to Ed, uh, Hall offered Hansen a discount and practically promised to get him to the top. And this time, Hansen reached the summit at around four o'clock in the afternoon, two hours past the normal cutoff. And he had almost nothing left for the descent at that point. And this storm comes in. Uh and Vistors actually was lower down on the mountain at that point with an
37:13
Unidentified speaker (speaker_0): IMAX team who were filming. that the movie uh Everest. I don't know if you guys have seen that. Um
37:18
Unidentified speaker (UNKNOWN): the
37:18
Unidentified speaker (speaker_0): next morning, uh so you know, they're out overnight up on the mountain. The next morning Ed is talking to his friend Hall on the radio and he's urging him to get m moving down, crawl if he has to, just keep moving. But but neither Hall or Hansen ended up making it home. At And that nineteen 1996 ninety-six uh trip on Everest
37:36
Unidentified speaker (UNKNOWN): was
37:36
Unidentified speaker (speaker_0): like one of the most deadly ever. It was a terrible year. Uh so imagine the pressure though of turning someone around who came back because he trusted you. And then that you know that would be so hard to keep your rule, right? Of two o'clock. That's why he broke it. So
37:49
Unidentified speaker (UNKNOWN): you're
37:49
Unidentified speaker (speaker_0): probably anticipating all the tortured analogies we're gonna we're gonna get into. Uh but the market has come a long way since 2009. You know, we're 17 years, half of a career at this point. And if you look at the chart of the SP for 500, if you go back, it looks like a big mountain. And the temptation is to ask, like, where is the summit? Uh, but the
38:09
Unidentified speaker (speaker_0): market doesn't really have a two o'clock like it, like an ed uh Vestors would say. Uh, you know, Toby, we've been saying it's two o'clock, or Cape has been saying it's two o'clock since you know 2015, right? So
38:21
Unidentified speaker (speaker_0): Uh but after after this long climb, the harder question might be what success has done. to our judgment now? The portfolios are gotten bigger, we get more comfortable with the potential risks. It looks like everything just kind of works pretty well, the world figures it out, the limits that we set years ago start to feel uncomfortably and unnecessarily
38:40
Unidentified speaker (speaker_0): cautious. And everyone around us is still climbing hard and uh like they're gonna make it to the top and we aren't. Uh and and we don't really stop to ask, like, what did we write down at Base Camp originally? Uh, how much of our money were we willing to expose to the market? How much leverage can we take? How much do we need to keep available so a bad market won't force us to sell? Um,
39:01
Unidentified speaker (UNKNOWN): our
39:01
Unidentified speaker (speaker_0): rules are have to protect our ability to live through a decline, right? I mean, this is sort of obvious stuff, but but they also uh obeying them carries a cost, it's expensive. And and you, you know, rebalancing hurts when markets are just keeping. just keep going up. Uh, you know, you reduce leverage, and your friends are now getting richer faster than you. That's that's a terrible thing to
39:21
Unidentified speaker (speaker_0): experience. So now you have this very persuasive reason why this is the time to make an exception. Isaac Newton did a version of this in the South Seas bubble. 1720, he sold his South Sea shares for a big gain. Then the price kept climbing and he bought back in at much higher prices and eventually.
39:39
Unidentified speaker (speaker_0): concentrating nearly his entire fortune in the company. And then the bubble broke and he lost everything, his profits and more. Uh and he'd already gotten to down from the mountain, but then he went back up it and he made one good decision, but then totally undid it with a bad decision. So last thing
39:55
Unidentified speaker (UNKNOWN): here.
39:56
Unidentified speaker (speaker_0): Climbers sometimes compare deaths with successful summits as a ratio, which is kind of interesting. Uh and on Annapurna, which is the deadliest mountain on the planet, there's about one death to every seven summits. But someone who turns around and comes home without reaching the top doesn't really add to either one of those numbers. And so now think about
40:16
Unidentified speaker (speaker_0): your portfolio. You know, we spent plenty of time measuring how much we made on the wins. But here's another number how much would you have to make to recover what you would lose or what you could lose? And we know the math behind this, right? Um lose 20% and you need 25% to get back to even. Lose half, you need to double your money, lose 80%, you need to get
40:35
Unidentified speaker (speaker_0): 400% in gains. So five times your remaining money basically just get just to get back where you started. Um so suddenly the person who came home without a summit looks a little bit different now. So so do the investors who had an unexciting year. They keep their capital intact. They still have the resources for another attempt, right? Like there's sort of
40:55
Unidentified speaker (speaker_0): this idea of variance strain that we've talked about on the show lots of times. It's um but that caution doesn't come for free, of course. Like you miss a lot of the upside and you can spend years looking foolish, uh, guilty as charge. So
41:08
Unidentified speaker (UNKNOWN): a
41:08
Unidentified speaker (speaker_0): sensible Simple decision can become very difficult to live with. Uh, and basically, you need to decide why while you're thinking clearly. and not under the up at the top of the mountain and pushing for that summit.
41:20
Unidentified speaker (UNKNOWN): So
41:20
Unidentified speaker (speaker_0): May of 2005, Anna Purna, Ed is looking at his watch. It's two o'clock, it's time to head down. 18 years he's been chasing this feat to get to those 14 highest mountains in the world on Earth. And he reaches his last summit, uh and he still has one job left to do, which is to get down and get home safe. safely to his wife and kids, and and
41:40
Unidentified speaker (speaker_0): he accomplishes it. And I I think it's really incredible to see somebody who
41:44
Unidentified speaker (UNKNOWN): we
41:44
Unidentified speaker (speaker_0): would from the outside say is taking incredibly dangerous risks, but he was so sensible about it that he probably wasn't taking as much risk as it would look like from the outside because he had these rules, because he trained so hard to be able to survive. Um so I thought I just s it's a great book. Pick it up and read it when you get a chance. Uh and there's the the the lessons for investors just like jump off the page at
42:04
Unidentified speaker (speaker_0): you.
42:05
Unidentified speaker (speaker_1): Okay. When I sell my business, I want the best tax and investment advice.
42:09
Unidentified speaker (speaker_0): I want to help my kids, and I want to give back to the community. Ooh, then it's the vacation of a lifetime.
42:17
Unidentified speaker (UNKNOWN): I
42:17
Unidentified speaker (speaker_0): wonder if my head of office has a forever setter.
42:20
Unidentified speaker (UNKNOWN): An
42:20
Unidentified speaker (speaker_1): IG private wealth advisor creates the clarity you need with plans that harmonize your business, your family? and your dreams. Get financial advice that puts you at the center. Find your advisor at IGPrivatewealth.com.
42:35
Unidentified speaker (speaker_2): The sports calendar is on fire, and
42:36
Unidentified speaker (UNKNOWN): the score bet has you covered with breaking news and betting seamlessly connected. Every play, every stat, every score, giving you the tools you need to bet confidently. Born in the North, built Bill for you. The Score Bet, Canada Sportsbook. Please play responsibly, 18 years old. or older.
42:51
Unidentified speaker (speaker_3): If gambling is affecting your mental health or well-being, help is available. In Alberta, call or text 211 or visit ab.211.ca. Standard message and data rates may apply.
43:06
Unidentified speaker (UNKNOWN): Good
43:07
Unidentified speaker (speaker_2): one, JT. Dave, If uh that's it does raise an interesting question for you. you you said that you're you're sort of valuation aware, but your quality growth. So what is your cell discipline around positions?
43:20
Unidentified speaker (speaker_1): Yeah, so um that that is uh an interesting anecdote on on the book. And I I could definitely make
43:26
Unidentified speaker (UNKNOWN): you
43:26
Unidentified speaker (speaker_1): know corollaries to our our portfolio and definitely a look over the last couple of years based on
43:31
Unidentified speaker (UNKNOWN): the
43:31
Unidentified speaker (speaker_3): type of manager we're at we are. But um in terms of the the valuation question, cell discipline, um I think that really embeds into, you know, once we've made the decision that that a company is that belongs in our portfolio, we do structure port price targets around it. And we do that for a few different reasons. Um we have upside and
43:51
Unidentified speaker (speaker_3): downside targets and also our base case price target. And we we invest based on our base case price target, and we're usually looking for a certain return, and that return um there's also a a qualitative factor, which is risk in the position. So obviously if we say we're looking for say a 15, 20% return in a in a normal stock, if we're investing in a
44:10
Unidentified speaker (speaker_3): small cap biotech company, the the risk, the return has to be higher because the risk is a lot higher. So when we set the the price targets, like we want to have a a certain amount of return that we can get. But then the the upside and downside price targets are there for for a few reasons. The downside price target is a pretty good predictor. of we found, and this isn't a study that we've done, but I
44:30
Unidentified speaker (speaker_3): think
44:30
Unidentified speaker (UNKNOWN): you can look and
44:31
Unidentified speaker (speaker_3): see the evidence that when the
44:33
Unidentified speaker (UNKNOWN): downside price target's breached, there's probably something wrong with our initial thesis. Like something's gone horribly
44:39
Unidentified speaker (speaker_3): wrong. That's very easy to see
44:40
Unidentified speaker (UNKNOWN): when you're investing in a biotech
44:41
Unidentified speaker (speaker_3): stock.
44:42
Unidentified speaker (UNKNOWN): When they fail a clinical trial
44:43
Unidentified speaker (speaker_3): and that
44:43
Unidentified speaker (UNKNOWN): was a major value
44:44
Unidentified speaker (speaker_3): driver,
44:45
Unidentified speaker (UNKNOWN): you know,
44:45
Unidentified speaker (speaker_3): you don't have to be a genius to understand something went wrong there. But with other businesses,
44:49
Unidentified speaker (UNKNOWN): like maybe
44:49
Unidentified speaker (speaker_3): it's
44:50
Unidentified speaker (UNKNOWN): a consumer business. or financials
44:52
Unidentified speaker (speaker_3): business, the downside price target is very, very um descriptive and usually, you know, an indication that something went wrong. But we also set the upside targets when things are going absolutely right. Um, so it gives us that flexibility on valuation to, okay, they've met our primary price target. This might be a sell signal or a sell signal and really
45:12
Unidentified speaker (speaker_3): to take profit. Um, but we might be in a situation where things are going, you know, as right as we would have expected them to go, which would give us, you know, some room to our upside price target. Uh so in terms of you know sell discipline, we are pretty evaluation conscious from uh we do pay attention to our price targets. Uh, if we see big moves in a
45:31
Unidentified speaker (speaker_3): stock and and our our price objectives are ever met, if we think there's too much euphoria in the stock and we really shouldn't be pricing in the upside, and then that really is what guides our our our self-discipline. And I'd say that we're pretty good at that.
45:43
Unidentified speaker (UNKNOWN): And
45:43
Unidentified speaker (speaker_2): what what do you revert to? Do you sell down into cash or do you just have a a a roster of the next name
45:49
Unidentified speaker (UNKNOWN): up?
45:51
Unidentified speaker (speaker_3): Yeah, I mean it it could go it can go either way.
45:54
Unidentified speaker (speaker_3): We will aggressively trim positions. it You know, if we think there's still some room or we think there might be uh you know that the upside that upside scenario is more likely than not, then those are instances where we're not going to sell the cash. We're gonna uh we're gonna um uh
46:09
Unidentified speaker (UNKNOWN): we're
46:09
Unidentified speaker (speaker_3): gonna hold on to some of the position but take some some off the table now because we've seen you know pretty dramatic move in the stock. And yeah, I think you know one of the the the lifebloods for for any portfolio manager or any portfolio is just a constant flow of ideas. And that's why we have a team that are constantly looking for forward for new ideas. myself included, to really rotate, to
46:29
Unidentified speaker (speaker_3): rotate fresh ideas into the portfolio to make sure that uh we're not holding on to things or staying, you know, staying in something too long or staying in something just to tie up capital, which is always a recipe for disaster.
46:41
Unidentified speaker (UNKNOWN): Why
46:41
Unidentified speaker (speaker_0): is it so expensive to get through clinical trials? Is it I've read somewhere it was like a hundred million dollars or something. Maybe that number is stale now and it's it's even more, but what's what's going on there?
46:54
Unidentified speaker (UNKNOWN): Well
46:55
Unidentified speaker (speaker_3): there there's there's a lot of costs that get that get rolled into to a clinical trial. Um having never run one, I can't tell you exactly what it is, but I I can tell you that um the CROs, uh the the the contract research organizations are pretty good at um at laying all this out. And you could talk to the biotech companies about what it costs to to run these things.
47:15
Unidentified speaker (speaker_3): But
47:17
Unidentified speaker (speaker_3): there's there are a lot of reasons for this. And some of the reasons are you have to set up sites and monitor these patients on a pretty aggressive basis. So obviously all the blood test scans, et cetera, that you have to do on a regular, on with regular frequency
47:33
Unidentified speaker (speaker_3): costs a decent amount of money. And that could be tens of thousands of dollars per patient per year. And imagine a trial, like I just mentioned, Dan Alzheimer's trial, if it has to last three plus years, or you're talking about a cardiovascular outcomes trial where they can last more than three years as well, and you can have thousands of patients in that study, and
47:53
Unidentified speaker (speaker_3): you're talking about 10,000 plus a patient per year, um the cost of running those trials gets gets pretty high.
48:02
Unidentified speaker (UNKNOWN): Um
48:02
Unidentified speaker (speaker_3): you're
48:03
Unidentified speaker (speaker_2): outsourcing, you're running at a lot of different sites. Obviously, like you can't run a clinical trial at just one hospital. You have to run it at multiple hospitals. In a lot of instances, when you're running in um in a lot of these harder to find indications, you're running in multiple countries globally. So that adds to logistical complexity. There's the cost of
48:22
Unidentified speaker (speaker_2): manufacturing the drug of which you have no offset, right? You know, you just it's pure co cost. So each each the cost of the drug, you know, is a is a
48:30
Unidentified speaker (UNKNOWN): is
48:30
Unidentified speaker (speaker_3): a portion of that ethical trial expenditure. Um so it's a lot of that gets gets rolled into it. But I think a lot of it is making sure that when the trial is complete, um, that you have a full and auditable set of data. Um, and that's just not cheap. The only way to bring down, and you know, maybe this is part of
48:50
Unidentified speaker (speaker_3): the promise. of AI, like I mentioned. Um, one of the things that that that you can help with down the line is if you are accurately selecting patient populations, uh, you're really sure that you are selecting the appropriate patient population for the drug that you're you're testing, you can start to
49:10
Unidentified speaker (speaker_3): reduce the sample size um because statistically you're you're hoping for. a a much cleaner outcome. And with that, cost should come in.
49:20
Unidentified speaker (speaker_0): Maybe we can see if uh Elizabeth Holmes could get that Thoranos thing working again and we could get the get the cost of blood testing lowered.
49:27
Unidentified speaker (speaker_2): Have you seen the documentary
49:30
Unidentified speaker (speaker_2): documentary?
49:30
Unidentified speaker (speaker_3): I think she's still in jail. I haven't I haven't watched the documentary yet, but I
49:33
Unidentified speaker (UNKNOWN): do
49:34
Unidentified speaker (speaker_3): but I but interestingly um I was on the sell side and I was covering life science tools and diagnostics when uh when that was when that was a thing. And I remember
49:44
Unidentified speaker (UNKNOWN): what
49:44
Unidentified speaker (speaker_0): did you think of that? You were like, this is this is insane.
49:46
Unidentified speaker (speaker_3): I mean what I what I would say is that I feel like it was a much
49:51
Unidentified speaker (UNKNOWN): I
49:51
Unidentified speaker (speaker_3): I don't mean to be disparaging at all, but I think there was a much greater interest from from retail investors on on that versus what what the institutional investors thought. And there was a lot of question coming out of the sell side to the point that one of my colleagues at another bank that was covering the space actually went,
50:11
Unidentified speaker (UNKNOWN): I don't
50:11
Unidentified speaker (speaker_3): know if it was CVS, CVS that had the deal with them to get a blood test. And you know how they how they were saying at the time that it was a you know a pinprick of blood. It was like they took a cuvette, attached it to his finger and squeezed his finger so hard to get blood to fill that cuvette. And when he told us that story, it was kind of like just perfect to
50:31
Unidentified speaker (speaker_3): hear.
50:32
Unidentified speaker (speaker_3): Um, but yeah.
50:34
Unidentified speaker (UNKNOWN): It
50:34
Unidentified speaker (speaker_2): seems like her thesis advisor was pretty skeptical the whole way through. It seems like it was like a fell it was like a known thing that it wasn't gonna work.
50:42
Unidentified speaker (speaker_3): I think parts of the test did work, but I uh what I also heard was they that were running running the blood samples through uh, you know, the traditional lab equipment, which is why they need needed the volume of blood they were trying to squeeze out of people.
50:54
Unidentified speaker (UNKNOWN): Tell
50:54
Unidentified speaker (speaker_0): me you gotta fake it till you make it my man. What
50:56
Unidentified speaker (UNKNOWN): if we've learned
50:57
Unidentified speaker (speaker_0): anything
50:59
Unidentified speaker (UNKNOWN): very
50:59
Unidentified speaker (speaker_0): thin line.
51:01
Unidentified speaker (speaker_3): That's right.
51:01
Unidentified speaker (UNKNOWN): Well
51:02
Unidentified speaker (speaker_2): I guess Netflix used to send out the DVDs right before you could download the
51:06
Unidentified speaker (UNKNOWN): watch
51:06
Unidentified speaker (speaker_2): it online.
51:07
Unidentified speaker (speaker_3): I just explained that to my kids recently that Netflix wasn't all online that it used you to be able to we used to have to you know time it so you can get the most DVDs you could possibly get. You were always cycling through the three. That's right.
51:18
Unidentified speaker (UNKNOWN): I actually kind
51:18
Unidentified speaker (speaker_0): of miss that. I I sort of, you know, it makes you made you appreciate sitting down to watch it together instead of just always having whatever streaming available.
51:26
Unidentified speaker (speaker_3): Yeah. Yeah. I mean, that's that's exactly right because you can't get everybody off the iPads now. You can't get everybody in front of a screen. They all want their own screen.
51:34
Unidentified speaker (speaker_0): Yeah.
51:36
Unidentified speaker (speaker_2): Um looking at some of the
51:37
Unidentified speaker (UNKNOWN): the
51:38
Unidentified speaker (speaker_2): uh biofarmer investments that have been acquired, Dave, what are the characteristics that those companies tend to share?
51:46
Unidentified speaker (speaker_3): Yeah, and I and like honestly, you you uh
51:48
Unidentified speaker (UNKNOWN): positive
51:49
Unidentified speaker (speaker_0): indication.
51:51
Unidentified speaker (speaker_3): I mean this this is this is interesting because you could you could look at um we could we could say this about the the names that have been acquired out of our our our portfolio as well. And I think um the things the things that these investments tend to share from a from an asset standpoint are um clean data
52:11
Unidentified speaker (speaker_3): packages, uh areas of unmet medical need, um novel novel uh novel compounds, um,
52:20
Unidentified speaker (speaker_3): or truly uh uh groundbreaking technology where there where there is actually a market. So like if if an asset is acquired, for example, in like you know an immunology space, like if you're looking at uh an anti-inflammatory or something, it it tends not to be, it tends not to be a a Mi
52:40
Unidentified speaker (speaker_3): three or a Mi four. It's a it's a new modality, you know, new, a new, a new target that is going to help expand the market or help you know move above some of the other therapies that are out there. Uh if I look at at our our acquired names and our portfolios, um there are like a lot of, you know, first to, first to category type
53:00
Unidentified speaker (speaker_3): medications that get acquired. Um so it's it's asset driven first. But you know, the other characteristic that we've noticed as well is is the management quality coming out of these things. Um like I like I mentioned before, you know, one of the reasons we think management quality is so important is it doesn't matter how good the asset is, if they can't navigate the developmental pathway, like when you think about
53:20
Unidentified speaker (speaker_3): small cap biotech or some of the other healthcare spaces or tech, it it doesn't matter because they'll screw it up along the way and you're going to lose money on that. So I think you know that's another thing that goes hand in hand. You usually have a very strong management team next to those assets that was able to navigate the developmental pathway. to really show the
53:40
Unidentified speaker (speaker_3): promise of the asset and then a very clean data package that's going to make a difference in that field. And that is usually the characteristic. And that's like a very amorphous answer because healthcare is so varied. It isn't like you're not looking at one indication, you're looking at so many different fields. But I think that is a As a as high level are the types of characteristics
54:00
Unidentified speaker (speaker_3): you see.
54:01
Unidentified speaker (UNKNOWN): Uh
54:01
Unidentified speaker (speaker_2): We got some reasonably well-informed. uh listeners. I got a good question here. Uh it's uh it's a little bit leading. I'm not going to lead the witness too much, but the question is about revolution medicines. Is that one that you
54:12
Unidentified speaker (UNKNOWN): uh have a
54:12
Unidentified speaker (speaker_2): view of?
54:13
Unidentified speaker (speaker_3): Yeah. Yeah.
54:14
Unidentified speaker (UNKNOWN): Can
54:14
Unidentified speaker (speaker_2): you tell us a little bit about revolution medicines? I'll I'll hit you with a few of the follow-up questions as we go along.
54:19
Unidentified speaker (speaker_3): Yeah, yeah. So so it's a name that that we've looked at for a while. And revolution medicine um
54:25
Unidentified speaker (speaker_3): develops small molecules to treat um cancer indications. And um this past year uh they've shown some pretty great data and had their first drug approval in uh pancreatic cancer. And as we know, um pancreatic cancer is basically a death sentence. Usually it's caught very late. Um,
54:45
Unidentified speaker (speaker_3): when it's caught late, uh there's there no surgical option and
54:50
Unidentified speaker (UNKNOWN): uh um
54:51
Unidentified speaker (speaker_3): you have very little time to live after diagnosis. And and they've shown in clinical trial um in refractory PDAC, which is a form of pancreatic cancer, that um they've more they they doubled overall survival. So the drug was approved. Uh first quarter sales were just posted. They did
55:10
Unidentified speaker (speaker_3): extraordinarily well. No good deed uh left unpunished. They beat street estimates probably by the high end of most estimates by four
55:22
Unidentified speaker (speaker_3): X at least. Stock went down on the print.
55:26
Unidentified speaker (speaker_3): But you know, they have a pretty rich developmental pipeline that's going to help them stay ahead. They're developing other other forms of the drug they've already developed to go after different uh different indications and also move. up the treatment paradigm. Um so I think you know there's there's a lot of upside. There's a lot of potential for for a company like Revolution Medicine.
55:45
Unidentified speaker (speaker_2): How big is it now?
55:47
Unidentified speaker (speaker_3): I think 40 plus billion, don't quote me. I'd have to open my Bloomberg and then a lot of noise will be made if I do that.
55:54
Unidentified speaker (UNKNOWN): The
55:54
Unidentified speaker (speaker_2): question is
55:54
Unidentified speaker (UNKNOWN): kind of out of the
55:55
Unidentified speaker (speaker_0): small cap, then though, I would assume.
55:57
Unidentified speaker (speaker_3): Uh yeah, that would fit more on the on the mid-cap side for us, which is uh you know an ever expanding you know market cap. range.
56:03
Unidentified speaker (speaker_0): Yeah.
56:04
Unidentified speaker (UNKNOWN): The
56:04
Unidentified speaker (speaker_2): leading question was can it hit a hundred billion plus market cap? But I guess that that's not impossible from 40 billion.
56:11
Unidentified speaker (speaker_3): No, no, not not impossible. Uh I think we've seen we've seen small cap, mid-cap companies, you know, get up there in size. I don't know where Vertex is trading these days, but that's a good example where they have a cystic fibrosis franchise that hit seven or eight or nine billion dollars of sales. I don't know what the exact number is right now, um,
56:31
Unidentified speaker (speaker_3): that expanded market cap, but you'd have to have something like that where they go beyond just the that second line PDAC setting they're in right now. They go into frontline, get the majority of that market and then also expand in other indications, which you know they're they're they're developing.
56:47
Unidentified speaker (UNKNOWN): You could
56:47
Unidentified speaker (speaker_3): paint the upside scenario. Sorry.
56:49
Unidentified speaker (speaker_0): What's a typical like duration of that kind of franchise? Like how long can you expect
56:54
Unidentified speaker (UNKNOWN): to
56:55
Unidentified speaker (speaker_0): earn pretty like super normal profits before either it comes off patent or someone comes up with a better version of trading that same thing?
57:04
Unidentified speaker (speaker_3): Yeah, yeah. So um
57:08
Unidentified speaker (UNKNOWN): so
57:08
Unidentified speaker (speaker_3): different for for small molecules and large molecules. Um so so uh revolution medicine's medicine is developing small molecules. So these are you know your standard pills, not I shouldn't say standard, because you honestly the innovation that Revolution did was they're very good medicinal chemists. They they were able to drug a target in a way that had not been
57:28
Unidentified speaker (speaker_3): drugged before, which is why they had such such success there. So can't discount that. And they also have other drugs that they're working on. Um, but patent life is 20 years, and that's that clock starts from invention. So you have 20 years and there's some ways to extend. So
57:45
Unidentified speaker (speaker_0): if it's 13 to get to development, you only have seven left typically on
57:49
Unidentified speaker (UNKNOWN): the roughly but there's there's other
57:51
Unidentified speaker (speaker_3): Yeah, there's other ways to extend that. Oh, based on
57:55
Unidentified speaker (speaker_0): funny delivery cap or something.
57:57
Unidentified speaker (UNKNOWN): Yeah,
57:57
Unidentified speaker (speaker_3): there's there's ways to engineer around patent, you know, like basically like method of use, et cetera. Um also there's pediatric extension, uh there's there's a lot of other things. If you're developing a biologic, the time frame's a little bit longer. The the the the government gives you a longer window to um to
58:16
Unidentified speaker (UNKNOWN): to
58:16
Unidentified speaker (speaker_3): basically have to basically have a uh uh
58:20
Unidentified speaker (UNKNOWN): to
58:20
Unidentified speaker (speaker_3): basically eliminate competition from from generic uh just based on on developing a large molecule. Um Also, the other thing I'd say, the reason I brought up the difference between small and large molecules is that inherently small molecules are easier to manufacture than a large molecule. Large molecules are it's a totally different manufacturing process where
58:40
Unidentified speaker (speaker_3): if you had a factory and I had a factory, we might not necessarily develop the same generic version of the large molecule that we wanted, which can extend a life cycle a little bit longer, which is why you've seen seen biosimilars, which is the generic version of biologics or large molecules, take a lot longer to become a thing
58:59
Unidentified speaker (speaker_3): in the in the healthcare world. But I'd say like it's probably fair to say that you get like 10 years of of exclusivity when when you have one of these drugs and and exclusivity on your specific molecule. That doesn't mean that someone can't come in and develop a better mousetrap based on what you're developed, but based on what you've developed.
59:19
Unidentified speaker (speaker_3): But there is a lot of visibility into that. Obviously, these things aren't done in a vacuum. Once the clinical trials start, we could see what's going on. They're presented at conferences, uh data, data are presented and published, et cetera. But I'd say 10 years is a good number. So in a company like Revolution Medicine, they're always thinking about how do I stack you know the next clinical trials to build my
59:39
Unidentified speaker (speaker_3): pipeline so that this isn't like this cliff immediately on one asset.
59:44
Unidentified speaker (speaker_2): Okay. When I sell my business, I want the best tax and investment advice. I want to help my kids, and I want to give back to the community. Ooh, then it's the vacation of a lifetime. I wonder if my head out of office has a forever setter.
59:59
Unidentified speaker (UNKNOWN): An
1:00:00
Unidentified speaker (speaker_1): IG private wealth advisor creates the clarity. you need with plans that harmonize your business, your family, and your dreams. Get financial advice that puts you at the center. Find your advisor at IGPrivatewealth.com.
1:00:14
Unidentified speaker (speaker_2): The sports calendar is on fire, and the score bet has you covered with breaking news and betting seamlessly connected. Every play, every stat, every score, giving you the tools you need to bet confidently. Born in the North, built for you. The score bet, Canada Sportsbook. Please play responsibly, 18 years or older.
1:00:30
Unidentified speaker (UNKNOWN): If
1:00:31
Unidentified speaker (speaker_1): gambling is affecting your mental health or well-being, help is available. In Alberta, call or text 211 or visit ab.211.ca. Standard message and data rates may apply.
1:00:45
Unidentified speaker (UNKNOWN): Dave,
1:00:46
Unidentified speaker (speaker_0): uh, last question.
1:00:47
Unidentified speaker (UNKNOWN): Are
1:00:47
Unidentified speaker (speaker_0): there any particular subsectors, themes, or companies you're especially excited
1:00:52
Unidentified speaker (UNKNOWN): about?
1:00:53
Unidentified speaker (speaker_3): Yeah, I mean, uh, you know, I started to say this before, and we've gotten a little bit more excited outside of of of bioforma and and medical devices recently. And I think you know, it's it's a it's an an interesting thing. One, uh I think med tech was on the outs for investors for um
1:01:11
Unidentified speaker (speaker_3): for for a for a long time, especially on the small to mid mid-cap cap side. And I think part of that was due to the hype around GLP1s. Um, we've seen all the benefits and positivity coming out of GLP1s that seemed to hit med tech names the hardest for a lot of different reasons. One on the cardiovascular side, there's all this benefit from taking a GLP1 on
1:01:31
Unidentified speaker (speaker_3): cardiovascular outcomes. So there was this thought that anything that was intervening in in vessels, the market. potential was gonna be was going to be lower because GLP1s were this magic cure all for that. Um there was also commentary about uh there's there's studies that have shown that GLP1s reduce you know the
1:01:51
Unidentified speaker (speaker_3): basically joint pain uh arthritis pain etc therefore hips and knees don't need to be done anymore um there was is obviously a extreme benefit on sleep apnea so anything that's used to intervene in sleep apnea, that's that's gone too.
1:02:06
Unidentified speaker (speaker_3): I think that's kind of worn away. I think we've seen uh we we know that there's a lot of cardiovascular disease that needs to be treated. Um there's a lot of other things that need to be treated where you know there's a lot of great medical device companies out there. Also, interestingly, on the uh on the orthopedic side, we've seen a whole spade of new types of injuries tied to things like paddle. So you know.
1:02:26
Unidentified speaker (speaker_3): maybe, maybe as we as we all lose more weight, we get more active and we have sports-related injuries, not just uh you know injuries related to
1:02:34
Unidentified speaker (speaker_0): couch-related injuries.
1:02:35
Unidentified speaker (speaker_3): Yeah, exactly. Exactly. So what we've seen is, and and I you know give a lot of credit to my colleagues on this one, is um uh real interest in in leaning into the med tech side just because they were at historical evaluation lows. lists. And we like med tech companies because
1:02:51
Unidentified speaker (speaker_3): to be public as a med tech company, for the most part, and there are exceptions to this, they have businesses.
1:02:58
Unidentified speaker (speaker_3): Most public investors don't tolerate don't tolerate uh unprofitable or or or medical device companies that don't have like actual revenues and real business uh tied to them. And also we've noticed is so so that's a good thing as a quality investor because we're actually getting a business for what we're buying. and not just a not just a dream. But we've also noticed is that there's
1:03:18
Unidentified speaker (speaker_3): two different flavors of med tech companies. There are those that are really high-tech, that have really deep regulatory motes that really resemble biotech companies. And we lean into those because there's high-tech, there's, there's, there's a lot more visibility into the revenue. There's there's a lot of the characteristics of the good biotech companies there. So we've been really leaning into those types of companies, names like
1:03:38
Unidentified speaker (speaker_3): Axegen. Axygen, Varacel, Cloudcost that are, you know, great growth businesses with not a lot of competition. And they have all of like the regulatory protections of those biotechs. We've seen a lot of opportunity there.
1:03:53
Unidentified speaker (speaker_2): Dave, uh, that's time. Uh, if folks want to follow along with what you're doing or get in touch, what's the best way of doing that?
1:03:59
Unidentified speaker (speaker_3): Uh, you can go to our website. It's uh www. www.tscmlc.com and there's a lot of links there.
1:04:07
Unidentified speaker (speaker_2): Good one. Uh JT, any fun of the words?
1:04:10
Unidentified speaker (UNKNOWN): No,
1:04:10
Unidentified speaker (speaker_0): thanks for coming on, Dave. It's good to talk to an expert in in something that that we don't know, which is most things. So that's what we'll it's a pretty open field, but uh but yeah, it's great to uh great to hear about your insights.
1:04:22
Unidentified speaker (UNKNOWN): Thanks for having me. Thank you, thank you very much,
1:04:24
Unidentified speaker (speaker_2): David.
1:04:25
Unidentified speaker (UNKNOWN): Thanks,
1:04:25
Unidentified speaker (speaker_0): guys. We'll be
1:04:26
Unidentified speaker (UNKNOWN): back uh next. week. Same bet
1:04:28
Unidentified speaker (speaker_2): time, sign
1:04:28
Unidentified speaker (UNKNOWN): bet channel.
1:04:29
Unidentified speaker (speaker_1): Introducing Hollywood Casino, Alberta's newest online casino experience. Get ready to take a holiday with all your favorite casino games. Immerse yourself in exclusive titles you won't find anywhere else. And spin into daily jackpots. Take a moment, take a holiday. Hollywood Casino. Please play responsibly, 18 years or
1:04:49
Unidentified speaker (speaker_1): older, Alberta only. If
1:04:50
Unidentified speaker (speaker_2): gambling is affecting your mental health and well being, 211 Alberta is here to help. Call or text 211 or visit ab.211.ca. Standard message and data rates may apply.
1:04:59
Unidentified speaker (UNKNOWN): In 2002, Ryan Wedding was an Olympic snowboarder at the top of his game.
1:05:05
Unidentified speaker (speaker_0): Ryan's style is really gunned and go.
1:05:07
Unidentified speaker (UNKNOWN): And in less than a minute, it slipped away. But he continued to chase
1:05:11
Unidentified speaker (speaker_1): the
1:05:11
Unidentified speaker (UNKNOWN): high.
1:05:12
Unidentified speaker (speaker_0): Brian James Wedding.
1:05:14
Unidentified speaker (UNKNOWN): He
1:05:14
Unidentified speaker (speaker_0): controls one of the most violent drug
1:05:16
Unidentified speaker (speaker_2): trafficking organizations in this world. I'm Michelle Shepherd, and from CBC Podcasts and the Toronto Star, The Most Wanted Olympian. The Most Wanted Olympian. Available now on Spotify.
This page was produced automatically: the audio was transcribed with nvidia/parakeet-tdt-0.6b-v3+sortformer-v2.1 and interpreted by Qwen3.6-35B-A3B-UD-IQ3_S.gguf. Transcription and interpretation can contain errors; always confirm against the original episode. Nothing here is investment advice.

More from The Acquirers Podcast

The Acquirers Podcast

Is AI Killing Adobe? We Discuss

Episode discussion: Tobias Carlisle and Tim discuss AI disruption risks to Adobe, Chegg, and data center politics.

Speakers’ claims: Tobias Carlisle and Tim analyze whether AI is killing Adobe, citing Chegg's 99% stock crash as an example of existential disruption. They debate if AI labs are infrastructure builders or retail layer users using Carlotta Perez's framework. Carlisle highlights political resistance to data centers despite their economic benefits. The speakers emphasize valuation discipline, noting that transformative tech can coexist with bubbles. They suggest using volatility to generate alpha through options strategies.

AI DisruptionValuationAdobe
41 min6 assets16 claims to verify
The Acquirers Podcast

Why Bill Ackman Loves Uber at 16x Earnings + Our 2 Favorite Cheap Stocks

Episode discussion: Carlisle questions AI capex sustainability while Travis highlights Uber and Ackman's insurance play

Speakers’ claims: Tobias Carlisle argues that the $7 trillion AI capex forecast is unrealistic given labor share constraints and points to hyperscalers' negative free cash flow as evidence of cyclical risk. Tim Travis discusses Uber's 25% annual profitability growth and Bill Ackman's strategy with Howard Hughes to launch an insurance subsidiary targeting 20% ROE. The hosts also analyze consumer stocks like Deckers and Lululemon, with Speaker 0 employing options strategies to capture premium in declining names. Carlisle contrasts the current market bifurcation with historical value trends, noting small-cap value outperformance in October 2026.

Small-cap valueAI CapexUber
50 min9 assets20 claims to verify
All insights